

Lewis Acid-Promoted Cyclization Reactions of Alkenyl Ethenetricarboxylates: Stereoselective Synthesis of 2-Oxotetrahydrofurans and 2-Oxopyrrolidines

Shoko Yamazaki,^{*,†} Ken Fujinami,[†] Yuki Maitoko,[†] Khota Ueda,[†] and Kiyomi Kakiuchi[‡]

[†]Department of Chemistry, Nara University of Education, Takabatake-cho, Nara 630-8528, Japan

[‡]Graduate School of Materials Science, Nara Institute of Science and Technology (NAIST), Takayama, Ikoma, Nara 630-0192, Japan

Supporting Information



ABSTRACT: Lewis acid-promoted intramolecular reactions of alkenyl ethenetricarboxylates and the corresponding amides have been examined. Reaction of allyl ethenetricarboxylates and the amides with Lewis acids (1–2 equiv) such as TiCl₄, TiBr₄, AlCl₃, and AlBr₃ gave 3,4-*trans*-halogenomethyl 2-oxotetrahydrofuran and pyrrolidine derivatives stereoselectively in high yields. The stereochemistries were determined by NOE experiments. Reaction of alkyl-substituted allylic ethenetricarboxylates with Lewis acids gave chloro 2-oxotetrahydrofurans and pyrans. For some alkyl-substituted substrates, cationic intermediates may be formed under the reaction conditions, and rearranged products have been obtained.



INTRODUCTION

Oxygen- and nitrogen-containing heterocyclic systems such as five-membered rings, tetrahydrofurans and pyrrolidines, are versatile core structures in organic chemistry because of their presence in many biologically active compounds.^{1,2} The development of new efficient synthetic strategies for the construction of these heterocycles is of considerable interest.^{3,4}

Snider and Roush reported that Lewis acid-promoted intramolecular reactions of alkenyl and alkynyl ethenetricarboxylates gave chlorinated γ -lactones (eq 1).⁵ We have developed Lewis



acid-promoted stereoselective cyclization of alkynyl ethenetricarboxylates with high generality (eq 2).⁶ Lewis acid-promoted intramolecular ene reaction⁷ and related cyclization of silicon-substituted allylic alkylidene 1,3-dioxo compounds to give carbocycles⁸ have also been reported. Furthermore, Lewis acid-promoted addition of simple alkenes to aldehydes proceeding to form C–C bonds (Prins reaction) is well-known.⁹ However, few Lewis acid-promoted Michael additions of simple alkenes such as allyl moieties have been reported. Related Lewis

acid-promoted reactions to give nitrogen-containing heterocycles may also be of interest.

We have studied various Lewis acid-promoted intermolecular reactions of ethenetricarboxylate derivatives and reported that they function as highly electrophilic Michael acceptors.¹⁰ In this work, Lewis acid-promoted intramolecular reaction of alkenyl ester and amides of ethenetricarboxylate leading to five-membered heterocycles has been examined. Furthermore, the scope and limitation of the Lewis acid-promoted intramolecular reactions of alkyl-substituted allylic esters have been described.

RESULTS AND DISCUSSION

Cyclization of Alkenyl Ethenetricarboxylates and the Amides. 2-Allyl 1,1-diethyl ethene-1,1,2-tricarboxylate (**1**) was previously used in TiCl₄-promoted intermolecular reaction with aminoacetals.^{10a} Competing intramolecular reaction was not observed under the reaction conditions. After examining various Lewis acids, it was found that reaction with AlCl₃, AlBr₃, TiCl₄, and TiBr₄ (1–2 equiv) at room temperature gave diethyl 2-(*trans*-4-(chloro (or bromo)methyl)-2-oxotetrahydrofuran-3-yl)-malonate (**2a,b**) in 57–90% yields (eq 3, Table 1). For AlCl₃, TiCl₄, and TiBr₄, use of 2 equiv of Lewis acids is required to drive the reaction to completion.

The γ -lactone structure of **2a,b** was suggested by the presence of a characteristic C=O absorption (1777–1779 cm⁻¹). ¹H, ¹³C and 2D NMR spectra were in agreement with the five-membered ring structure. The 3,4-stereochemistry of **2a,b** was examined by NOESY experiments. NOEs between H-3 and H-4 could be observed for both 3,4-*cis* and *trans* diastereomers. The following peaks were used for the assignment of the obtained single

Received: May 21, 2013

Published: July 25, 2013


Table 1. Reactions of Allyl Ester 1

entry	MX_n	MX_n (equiv)	2	yield (%)
1	AlCl_3	1	2a	58 ^a
2	AlCl_3	2	2a	72
3	AlBr_3	1	2b	57
4	AlBr_3	2	2b	45
5	TiCl_4	1	2a	^b
6	TiCl_4	2	2a	90
7	TiBr_4	1	2b	^b
8	TiBr_4	2	2b	62


^aA small amount of the starting material 1 could not be removed.

^bThe mixture including 1 and 2a/2b was obtained and could not be purified.


diastereomer. NOEs between H-3 and CH_2X ($\text{X} = \text{Cl}, \text{Br}$) and between H-4 and $\text{CH}(\text{CO}_2\text{Et})_2$ were observed. Thus, the 3,4-*trans* stereochemistry of 2a,b was determined.




The reaction of 1 with 2 equiv of FeCl_3 at room temperature for 17 h gave the noncyclized H_2O -adduct 3 in 42% yield as a major product. The reaction of 1 with 2 equiv of ZnI_2 at room temperature gave 3 in 59% yield as a major product, and the reaction at 80 °C in 1,2-dichloroethane gave only starting material 1.^{11,12} The reaction of 1 with 2 equiv of TiCl_4 at -40 °C gave the noncyclized Cl-adduct 4 in 77% yield as a major product. Formation of compounds 3 and 4 may be reversible as they were converted to 2a by treatment with 2 equiv of TiCl_4 at room temperature in 61 and 86%, respectively. Alternatively, compounds 3 and 4 may be intermediates en route to lactones 2.



The reaction of 3-butenyl ester 5 with 1–2 equiv of TiCl_4 or AlCl_3 was also examined. However, the reaction gave complex mixtures. Six-membered ring formation from 5 was not an efficient process.




The reaction of (*E*)-2-butenyl esters 6a,b with Lewis acid was next examined. The (*E*)-2-butenyl dimethyl ester 6b is the substrate that Snider and Roush reported.⁵ The reaction with 1 equiv of AlCl_3 or FeCl_3 at room temperature overnight gave diethyl 2-(4-(2-chloroethyl)tetrahydro-2-oxofuran-3-yl)malonates 7a,b as major products (eq 4). The ¹H NMR and IR spectral data for the product 7b are identical with the reported ones. The 3,4-*trans* stereochemistry for 7a,b was suggested by NOESY



experiments. NOEs between H-3 and CHClMe and between H-4 and $\text{CH}(\text{CO}_2\text{Et})_2$ were observed. Thus, the *cis* stereochemistry of 7b assigned in the literature is corrected to *trans*.¹³

The major products 7a and 7b are single diastereoisomers. The relative configuration of CHClMe to C-3, C-4 for diastereomers 7a,b could be deduced as (3*S*,4*S*)-4-((*R*)-1-chloroethyl) (shown in eq 4) and (3*R*,4*R*)-4-((*S*)-1-chloroethyl) by the similar reaction mechanism for the reaction of 1 (Scheme 1, vide post). The proposed reaction mechanism for the reaction of 6 to 7 is shown in Supporting Information.

Amide substrates 8a–c were then prepared by the condensation reaction of 1,1-diethyl 2-hydrogen ethenetricarboxylate (prepared from 1,1-diethyl 2-*tert*-butyl ethenetricarboxylate upon treatment with $\text{CF}_3\text{CO}_2\text{H}$) with the corresponding amines in the presence of HOBT, EDCI and Et_3N . Reaction of diethyl 2-((*N*-allyl-*N*-methylcarbamoyl)methylene)malonate (8a) with 1–2 equiv of TiCl_4 , FeCl_3 , AlCl_3 , TiBr_4 , and AlBr_3 at room temperature and ZnI_2 at 80 °C gave diethyl 2-(*trans*-4-(chloro(or bromo/iodo)methyl)-1-methyl-2-oxopyrrolidin-3-yl)malonate 9a–c in 69–98% yields (eq 5, Table 2). Use of




2 equiv of Lewis acids such as FeCl_3 , AlCl_3 , and ZnI_2 increased product yields. SnCl_4 and ZnBr_2 are less effective than TiCl_4 and TiBr_4 (entries 2,3,10). Reaction of *N,N*-diallyl and *N*-allyl-*N*-propylcarbamoyl derivatives 8b,c also gave 3,4-*trans*-pyrrolidines 9d–i efficiently. The γ -lactam structures of 9a–i were suggested by the presence of a characteristic $\text{C}=\text{O}$ absorption (1688–1698 cm^{-1}). ¹H, ¹³C and 2D NMR spectra were in agreement with the 5-membered ring structure. The 3,4-*trans* stereochemistry was determined by NOEs for I-adducts 9c,f,i in CDCl_3 and for Cl- and Br-adducts 9a,b,d,e,g,h in C_6D_6 .^{14,15} NOEs between H-3 and CH_2X ($\text{X} = \text{Cl}, \text{Br}, \text{I}$) and between H-4 and $\text{CH}(\text{CO}_2\text{Et})_2$ were observed.

Thus, use of strong Lewis acids leads to efficient five-membered cyclization of the allyl substrates. In the cyclization, the 3,4-*trans* stereochemistry does not depend on Lewis acids.

The reaction mechanism to give the halogenated five-membered heterocycles with 3,4-*trans* stereochemistry is proposed and shown in Scheme 1. *trans* precursor A1 and *cis* precursor A2 in Scheme 2 may be formed from 1 and Al_2Cl_6 reversibly. The reaction may start from the precursor A1 consisting of 1 and Al_2Cl_6 . The C–C bond formation and Cl–C bond formation from A1 may occur concertedly to lead to cyclized intermediate B1. Intermolecular Cl^- anti-attack leading to 3,4-*trans* cyclized product is proposed by steric reason. One molecule of Lewis acid (for example, AlCl_3) may work as a

Scheme 1. Proposed Reaction Mechanism for Cyclization of Allyl Esters 1 (R = Et) and B3LYP/6-31G*-Optimized Structures and Gibbs Free Energies (T = 298.15 K and P = 1 atm) for Intermediates and TS of the Model Compounds (1m (R = Me) + Al₂Cl₆)^a



^aTS geometry was characterized by vibrational analysis, which checked whether the obtained geometry has single imaginary frequencies (ν^{\ddagger}). From TS, reaction paths were traced by the intrinsic reaction coordinate (IRC) method to obtain the energy-minimum geometries.

catalyst and could be released after the cyclization step. Protonation and removal of AlCl₂OH yield the product **2**.

In order to support this hypothesis, the structures of the intermediates and transition states (TS) of model compounds (the corresponding methyl esters and Al₂Cl₆) were calculated using B3LYP/6-31G*. ΔG^{\ddagger} for TS1 leading to 3,4-*trans*-tetrahydrofuran is found to be lower than that of TS2 leading to 3,4-*cis*-tetrahydrofuran (Scheme 2). According to the observed *trans* selectivity and preferable use of excess Lewis acids in some cases, the proposed mechanism involving Al₂Cl₆ is likely.¹⁶ Cyclization mechanism and the stereochemistry of (*E*)-2-butenyl esters (**6** in eq 4) and allyl amides (**8** in eq 5) were also calculated by using the model compounds **6b** and the corresponding dimethyl ester of **8a** with Al₂Cl₆. These calculation results are similar to that for **1m** + Al₂Cl₆. Thus, formation of 3,4-*trans* five-membered rings are lower energy process than that of 3,4-*cis*. The results are shown in Supporting Information.


Next, reductive dechlorination of tetrahydrofuran and pyrrolidine was performed as an example of transformation of

Table 2. Reactions of Allyl Amides 8


entry	R ⁿ	MX _n	MX _n (equiv)	temp (°C)	X	yield (%)	
1	Me	TiCl ₄	1	rt	9a	Cl	98
2	Me	SnCl ₄	1	rt	9a	Cl	28
3	Me	SnCl ₄	2	rt	9a	Cl	38
4	Me	FeCl ₃	1	rt	9a	Cl	17
5	Me	FeCl ₃	2	rt	9a	Cl	83
6	Me	AlCl ₃	1	rt	9a	Cl	65 ^a
7	Me	AlCl ₃	2	rt	9a	Cl	76
8	Me	AlBr ₃	1	rt	9b	Br	69
9	Me	TiBr ₄	1	rt	9b	Br	87
10	Me	ZnBr ₂	1	rt	9b	Br	47
11	Me	ZnI ₂	1 × 2 ^b	rt	9c	I	73
12	Me	ZnI ₂	2	80 ^c	9c	I	69
13	CH ₂ CH=CH ₂	TiCl ₄	1	rt	9d	Cl	86
14	CH ₂ CH=CH ₂	TiBr ₄	1	rt	9e	Br	71
15	CH ₂ CH=CH ₂	ZnI ₂	1 × 2 ^b	rt	9f	I	59
16	CH ₂ CH=CH ₂	ZnI ₂	2	80 ^c	9f	I	77
17	CH ₂ CH ₂ CH ₃	TiCl ₄	1	rt	9g	Cl	48 ^a
18	CH ₂ CH ₂ CH ₃	TiCl ₄	2	rt	9g	Cl	98
19	CH ₂ CH ₂ CH ₃	FeCl ₃	2	rt	9g	Cl	54
20	CH ₂ CH ₂ CH ₃	TiBr ₄	1	rt	9h	Br	88
21	CH ₂ CH ₂ CH ₃	ZnI ₂	1 × 2 ^b	rt	9i	I	67
22	CH ₂ CH ₂ CH ₃	ZnI ₂	2	80 ^c	9i	I	87

^aA small amount of starting material and impurity could not be removed. ^bThe reaction with ZnI₂ (1 equiv) for 17 h gave the crude products including impurities (possibly noncyclized water-adducts) after workup. The crude products were further treated with ZnI₂ (1 equiv) to give the pure products **9c,f,i**. ^cIn CH₂ClCH₂Cl.


the halogenated products. The reaction of **2a** or **9a** with Bu₃SnH and AIBN gave dechlorinated tetrahydrofuran **10** and pyrrolidine **11**, respectively (eq 6). The stereochemistry of **11** was determined as 3,4-*trans* by NOESY experiment.



Cyclization of Alkyl Substituted Allylic Ethenetricarboxylates. Reactions of alkyl-substituted allylic ethenetricarboxylates with Lewis acids were investigated. The alkyl substitution pattern of allylic esters have been studied for mainly R³/R^{3'} = Me or Ph (dimethyl esters) by Snider and Roush (eq 1) and in this study (eq 4). In order to examine the effect of alkyl substitution of R¹/R^{1'}, R², the reaction of substrates shown below under similar reaction conditions were carried out.




The reaction of **12** with AlCl₃, TiCl₄ and FeCl₃ (1–2 equiv) at room temperature gave mixtures of 5-methyl-2-oxotetrahydrofuran **13** and *trans*-4-(1-chloroethyl)-2-oxotetrahydrofuran **7a** in ratios 1.3:1 to 0.3:1 (**13**:**7a**; eq 7). The isomeric mixture

Scheme 2. Reaction Pathway Leading to 3,4-*cis* Intermediate B2 for Model Compounds ($1m + Al_2Cl_6$)^a



^aB3LYP/6-31G*-optimized structures of the model compounds are shown. The Gibbs free energies are relative to **A1** ($R = Me$) in Scheme 1.

could not be separated. The compound **7a** is the product by the reaction of **6a** shown in eq 4, i.e., the structural isomer of **12**.



Similarly, the reaction of **14** with $AlCl_3$, $TiCl_4$ and $FeCl_3$ (1 equiv) at room temperature overnight gave 4-*trans*-(2-chloro-2-propenyl)-2-oxotetrahydrofuran **15** in low yields, along with 2-propenyl derivative **16** (eq 8). The compound **15** and the ene product **16** were also obtained by the reaction of **17** (eq 9). The reaction of **17** is similar to that of the corresponding methyl ester that Snider and Roush reported.⁵ The stereochemistry of the products **15** and **16** were determined as 3,4-*trans* by NOESY spectra.¹⁷


Formation of **7a** from **12** and **15** from **14** may be explained as follows. Secondary or tertiary allylic cation intermediate **I** may be formed by Lewis acid in situ. The isomerization of the ester **12** to **6a** and the ester **14** to **17** may lead to cyclization of **6a** to **7a** and **17** to **15** (Scheme 3). The substrate **14** rearranges to **17** via the stable tertiary allylic cation **I** ($R^1 = R^{1'} = Me$)




prior to cyclization of **14**. The substrate **17** may be thermodynamically more stable than **14**, because of the more substituted alkenyl group.

Related Lewis acid-catalyzed C–O scission and subsequent cycloaddition of 2-tertiary alkyl ester of ethenetricarboxylate has been reported previously.¹⁸ B3LYP3/6-31G* optimized structure of model compound **14m** (for ethenetricarboxylate **14**) with $AlCl_3$ coordinated at 2-ester oxygen has longer C–O


Scheme 3. Proposed Mechanism for Formation of 7a from 12 and 15 from 14



distance (1.586 Å) than that of **1m** + AlCl₃ (1.502 Å), which shows the ion pair character of **14m** + AlCl₃.



Interestingly, the reaction of **18** with AlCl₃ (1 equiv) gave 5-chloro-5-methyl-2-oxotetrahydro-2H-pyran **19** as an isolable major product (eq 10). The δ -lactam structure of **19** was



suggested by the observed C=O absorptions (1738 cm⁻¹ together with ethyl esters). ¹H, ¹³C and 2D NMR spectra were in agreement with the six-membered ring structure. Assuming the stable C-3 equatorial (CH(CO₂Et)₂) conformation and the absence of NOE peaks between H-3 (axial) and 5-CH₃ suggest the stereochemistry of **19** as shown in eq 10. Use of FeCl₃ or TiCl₄ also gave compound **19** in lower yield with a complex mixture. The reaction of **18** with TiCl₄ (1 equiv) at -40 °C for 20 h gave the noncyclized Cl-adduct **20** in 42% yield as a major product (eq 11), similar to the reaction of **1**. Treatment of **19** with AlCl₃ (1 equiv) at room temperature gave **20** in 50% yield.

Formation of **19** could be considered as follows (Scheme 4). The first cyclization to give the five-membered ring intermediate **B3** may occur by kinetically favored process, similar to Scheme 1. Alkyl group migration of **B3** may lead to

the stable tertiary cation six-membered ring intermediate **C3**. The attack of chloride ion from anti and syn sides of the malonate on the carbocation **C3** may be reversible. The observed diastereoselectivity of compound **19** may arise from the stable 1,3-diequatorial (CH(CO₂Et)₂) (on C-3) and larger CH₃ (on C-5) of the six-membered ring with smaller chlorine atom (on C-5) in the axial position. Thus, the attack of chloride ion to **C3** from anti-side of the malonate gives intermediate **D3** (path a).

Alternatively, intramolecular reaction of alkene moiety gives the stable tertiary cation six-membered ring intermediate **C3** (path b), followed by Cl⁻ attack leading to **D3**. Or, six-membered formation along with attack of Cl⁻ may lead to intermediate **D3** from **A3** directly (path c). Dyotropic rearrangement of the five-membered intermediate **B3** to six-membered ring intermediate **D3** (path d) is also possible.¹⁹

The reaction paths were examined using model compounds (the corresponding methyl esters and Al₂Cl₆). Only path a has been obtained by the model calculations.^{20,21} The TS energies of TS4 and TS5 are lower than the five-membered ring formation TS3. Six-membered ring intermediate **D3** may form intermediate **D'3** by removal of catalytic AlCl₃. Intermediate **D'3** is slightly more stable than the five-membered intermediate **B'3**, which may be formed from **B3**. Protonation of the intermediate **D'3** yields the product **19**. The six-membered diastereomers, **E3** and **E'3**, which may be formed reversibly, are thermodynamically less stable than **D3** and **D'3**, respectively, as discussed above. Further synthetic application and detailed mechanistic study for the six-membered ring formation are under investigation. Thus, for some alkyl-substituted substrates, cationic intermediates may be formed under the reaction conditions, and rearranged products have been obtained.²²

In summary, a Lewis acid-promoted reaction of alkenyl ethenetricarboxylates and the corresponding amides to give 3,4-*trans*-halogenomethyl 2-oxotetrahydrofuran and pyrrolidine derivatives has been found. The reaction proceeds stereoselectively. Strong Lewis acids such as TiCl₄ and AlCl₃ work efficiently. The highly functionalized and halogenated five-membered heterocyclic compounds generated in this reaction should be useful synthetic intermediates. Studies of the detailed reaction mechanism and transformations of the functionalized cyclic compounds are under investigation.


EXPERIMENTAL SECTION

General Methods. ¹H chemical shifts are reported in ppm relative to Me₄Si. ¹³C chemical shifts are reported in ppm relative to CDCl₃ (77.1 ppm). ¹³C multiplicities were determined by DEPT and HSQC. Peak assignments are made by 2D COSY, HSQC, NOESY, and HMBC spectra.

Ethenetricarboxylate **1** was prepared according to the literature.^{10a} **6b** was prepared according to the literature.²³

Ethenetricarboxylates **5**, **6a**, **12**, **14**, **15**, **17** and **18** were prepared by the reaction of diethyl ketomalonnate with the corresponding (triphenylphosphoranylidene)acetate according to the literature procedure.^{10a,17} These (triphenylphosphoranylidene)acetate esters were prepared by the corresponding chloroacetates and triphenylphosphine in benzene and subsequent treatment with NaOH. The chloroacetates were prepared by the reaction of the corresponding alcohols (1 equiv) and chloroacetyl chloride (1 equiv) in the presence of pyridine (1 equiv) in ether at 0 °C. Data of the ethenetricarboxylates and chloroacetates for new (triphenylphosphoranylidene)acetate esters are shown below.

3-Butenyl 2-chloroacetate. (69.3 mmol scale, 9.14 g, 89%); colorless oil: bp 81–82 °C/4.2 mmHg; ¹H NMR (400 MHz, CDCl₃)

Scheme 4. Proposed Mechanism for Formation of 19 from 18^a

^aProposed reaction mechanism for cyclization of 18 (R = Et) and model compound 18m (R = Me) with Al_2Cl_6 and the B3LYP/6-31G* calculated Gibbs free energies ($T = 298.15$ K and $P = 1$ atm) for intermediates and TS of the model compounds (18m + Al_2Cl_6). The B3LYP/6-31G* calculated Gibbs free energies { } for B'3, D'3 and E'3 are relative to B'3.

δ (ppm) 2.43 (tddd, $J = 6.8, 6.8, 1.4, 1.4$ Hz, 2H), 4.07 (s, 2H), 4.25 (t, $J = 6.8$ Hz, 2H), 5.10 (ddt, $J = 10.3, 1.6, 1.3$ Hz, 1H), 5.13 (ddt, $J = 17.0, 1.6, 1.6$ Hz, 1H), 5.78 (ddt, $J = 17.0, 10.3, 6.8$ Hz, 1H); ^{13}C NMR (100.6 MHz, CDCl_3) δ (ppm) 32.9 (t), 40.9 (t), 65.2 (t), 117.7 (t), 133.4 (d), 167.4 (s); IR (neat) 3081, 2962, 1759, 1643, 1415, 1313, 1290, 1183, 989, 922 cm^{-1} ; MS (CI) m/z 151 ($[\text{M} + 1]^+$, 35), 149 ($[\text{M} + 1]^+$, 100%); HRMS $[\text{M} + 1]^+$ 149.0372, 151.0337 (calcd for $\text{C}_6\text{H}_{10}\text{ClO}_2$ $[\text{M} + 1]^+$ 149.0369, 151.0340). Anal. Calcd for $\text{C}_6\text{H}_9\text{ClO}_2$: C, 48.50; H, 6.11. Found: C, 48.57; H, 6.20.

1-(3-Butenyl) 2,2-diethyl ethene-1,2,2-tricarboxylate (5). (16.3 mmol scale, 2.88 g, 65%); colorless oil: ^1H NMR (400 MHz, CDCl_3) δ (ppm) 1.32 (t, $J = 7.1$ Hz, 3H), 1.36 (t, $J = 7.1$ Hz, 3H), 2.43 (tddd, $J = 6.8, 6.8, 1.4, 1.4$ Hz, 2H), 4.24 (t, $J = 6.8$ Hz, 2H), 4.30 (q, $J = 7.1$ Hz, 2H), 4.38 (q, $J = 7.1$ Hz, 2H), 5.10 (ddt, $J = 10.3, 1.6, 1.1$ Hz, 1H), 5.13 (ddt, $J = 17.0, 1.6, 1.6$ Hz, 1H), 5.78 (ddt, $J = 17.0, 10.3, 6.8$ Hz, 1H), 6.87 (s, 1H); ^{13}C NMR (100.6 MHz, CDCl_3) δ

(ppm) 13.9 (q), 14.0 (q), 32.8 (t), 62.1 (t), 62.5 (t), 64.8 (t), 117.7 (t), 129.9 (d), 133.4 (d), 139.1 (s), 162.3 (s), 163.6 (s), 164.3 (s); IR (neat) 2984, 1726, 1644, 1467, 1373, 1346, 1258, 1182, 1067, 1024 cm^{-1} ; MS (CI) m/z 271 ($[\text{M} + 1]^+$); HRMS 271.1187 (calcd for $\text{C}_{13}\text{H}_{19}\text{O}_6$ $[\text{M} + 1]^+$ 271.1182). Anal. Calcd for $\text{C}_{13}\text{H}_{18}\text{O}_6$: C, 57.77; H, 6.71. Found: C, 57.60; H, 6.90.

1-((E)-2-Butenyl) 2,2-diethyl ethene-1,2,2-tricarboxylate (6a). (15 mmol scale, 2.90 g, 72%); colorless oil: ^1H NMR (400 MHz, CDCl_3) δ (ppm) 1.32 (t, $J = 7.1$ Hz, 3H), 1.35 (t, $J = 7.1$ Hz, 3H), 1.73 (bd, $J = 6.4$ Hz, 3H), 4.30 (q, $J = 7.1$ Hz, 2H), 4.36 (q, $J = 7.1$ Hz, 2H), 4.61 (d-like, $J = 6.6$ Hz, 2H), 5.59 (dtq, $J = 15.0, 6.6, 1.6$ Hz, 1H), 5.83 (dq, $J = 15.1, 6.4, 1.1$ Hz, 1H), 6.87 (s, 1H); ^{13}C NMR (100.6 MHz, CDCl_3) δ (ppm) 13.95 (q), 14.01 (q), 17.8 (q), 62.1 (t), 62.5 (t), 66.5 (t), 124.2 (d), 130.0 (d), 132.7 (d), 139.1 (s), 162.3 (s), 163.4 (s), 164.3 (s); IR (neat) 2984, 1726, 1650, 1447, 1372, 1345, 1257, 1179, 1067, 1022, 969 cm^{-1} ; MS (CI) m/z 271 ($[\text{M} + 1]^+$);

HRMS $[M + 1]^+$ 271.1180 (calcd for $C_{13}H_{19}O_6$ $[M + 1]^+$ 271.1182). Anal. Calcd for $C_{13}H_{18}O_6$: C, 57.77; H, 6.71. Found: C, 57.70; H, 6.82.

3-Buten-2-yl 2-chloroacetate. (30.4 mmol scale, 4.25 g, 94%); colorless oil: bp 65–66 °C/4.2 mmHg; 1H NMR (400 MHz, $CDCl_3$) δ (ppm) 1.37 (d, $J = 6.6$ Hz, 3H), 4.06 (s, 2H), 5.19 (ddd, $J = 10.4$, 1.2, 1.2 Hz, 1H), 5.30 (ddd, $J = 17.2$, 1.2, 1.2 Hz, 1H), 5.42 (qddd, $J = 6.6$, 6.0, 1.2, 1.2 Hz, 1H), 5.85 (ddd, $J = 17.2$, 10.4, 6.0 Hz, 1H); ^{13}C NMR (100.6 MHz, $CDCl_3$) δ (ppm) 19.8 (q), 41.1 (t), 73.2 (d), 116.8 (t), 136.7 (d), 166.5 (s); IR (neat) 3091, 2987, 1753, 1647, 1452, 1414, 1288, 1187, 1138, 1044, 992, 953 cm^{-1} ; MS (CI) m/z 151 ($[M + 1]^+$, 30), 149 ($[M + 1]^+$, 100%); HRMS $[M + 1]^+$ 149.0358, 151.0307 (calcd for $C_6H_9ClO_2$ $[M + 1]^+$ 149.0369, 151.0340). Anal. Calcd for $C_6H_9ClO_2$: C, 48.50; H, 6.11. Found: C, 48.42; H, 6.21.

1-(3-Buten-2-yl) 2,2-diethyl ethene-1,2,2-tricarboxylate (12). (18.2 mmol scale, 3.07 g, 62%); colorless oil: 1H NMR (400 MHz, $CDCl_3$) δ (ppm) 1.32 (t, $J = 7.1$ Hz, 3H), 1.35 (t, $J = 7.1$ Hz, 3H), 1.36 (d, $J = 6.4$ Hz, 3H), 4.30 (q, $J = 7.1$ Hz, 2H), 4.36 (q, $J = 7.1$ Hz, 2H), 5.18 (ddd, $J = 10.6$, 1.2, 1.2 Hz, 1H), 5.28 (ddd, $J = 17.2$, 1.2, 1.2 Hz, 1H), 5.43 (qddd, $J = 6.4$, 6.0, 1.2, 1.2 Hz, 1H), 5.84 (ddd, $J = 17.2$, 10.6, 6.0, 1H), 6.87 (s, 1H); ^{13}C NMR (100.6 MHz, $CDCl_3$) δ (ppm) 13.96 (q), 14.03 (q), 19.8 (q), 62.1 (t), 62.5 (t), 72.8 (d), 116.8 (t), 130.3 (d), 136.7 (d), 138.9 (s), 162.4 (s), 162.8 (s), 164.3 (s); IR (neat) 2983, 1735, 1725, 1647, 1448, 1375, 1260, 1184, 1066 cm^{-1} ; MS (CI) m/z 271 ($[M + 1]^+$); HRMS $[M + 1]^+$ 271.1189 (calcd for $C_{13}H_{19}O_6$ $[M + 1]^+$ 271.1182). Anal. Calcd for $C_{13}H_{18}O_6$: C, 57.77; H, 6.71. Found: C, 57.52; H, 6.78.

2-Methyl-3-buten-2-yl 2-chloroacetate. (30.4 mmol scale, 3.73 g, 75%); colorless oil: bp 95–105 °C/53 mmHg; 1H NMR (400 MHz, $CDCl_3$) δ (ppm) 1.57 (s, 6H), 3.99 (s, 2H), 5.13 (dd, $J = 10.9$, 0.6 Hz, 1H), 5.23 (dd, $J = 17.5$, 0.6 Hz, 1H), 6.08 (dd, $J = 17.5$, 10.9 Hz, 1H); ^{13}C NMR (100.6 MHz, $CDCl_3$) δ (ppm) 26.3 (q), 41.9 (t), 83.3 (s), 113.8 (t), 141.5 (d), 166.0 (s); IR (neat) 2985, 1754, 1414, 1382, 1367, 1314, 1199, 1123 cm^{-1} ; MS (EI) m/z 165 ($[M + 1]^+$, 39), 163 ($[M + 1]^+$, 100%); HRMS $[M + 1]^+$ 163.0527 (calcd for $C_7H_{12}ClO_2$ $[M + 1]^+$ 163.0526), M^+ 162.0452 (calcd for $C_7H_{11}ClO_2$ M^+ 162.0448).

1,1-Diethyl 2-(2-methyl-3-buten-2-yl) ethene-1,1,2-tricarboxylate (14). (11.8 mmol scale, 1.39 g, 41%); colorless oil: 1H NMR (400 MHz, $CDCl_3$) δ (ppm) 1.31 (t, $J = 7.1$ Hz, 3H), 1.34 (t, $J = 7.1$ Hz, 3H), 1.56 (s, 6H), 4.29 (q, $J = 7.1$ Hz, 2H), 4.35 (q, $J = 7.1$ Hz, 2H), 5.12 (dd, $J = 10.9$, 0.7 Hz, 1H), 5.21 (dd, $J = 17.4$, 0.5 Hz, 1H), 6.08 (dd, $J = 17.4$, 10.9 Hz, 1H), 6.82 (s, 1H); ^{13}C NMR (100.6 MHz, $CDCl_3$) δ (ppm) 13.96 (q), 14.04 (q), 26.3 (q), 62.0 (t), 62.4 (t), 83.1 (s), 113.7 (t), 131.8 (d), 137.9 (s), 141.5 (d), 162.4 (s), 162.6 (s), 164.3 (s); IR (neat) 2984, 1725–1742, 1645, 1468, 1447, 1376, 1349, 1265, 1188, 1126, 1066, 1023 cm^{-1} ; MS (EI) m/z 284 (M^+ , 0.4), 200 (42), 154 (68), 143 (80), 69 (100%); HRMS M^+ 284.1261 (calcd for $C_{14}H_{20}O_6$ M^+ 284.1260).

1,1-Diethyl 2-(3-methylbut-2-enyl) ethene-1,1,2-tricarboxylate (17). (14.9 mmol scale, 2.32 g, 55%); pale yellow oil: 1H NMR (400 MHz, $CDCl_3$) δ (ppm) 1.32 (t, $J = 7.1$ Hz, 3H), 1.35 (t, $J = 7.1$ Hz, 3H), 1.72 (narrow multiplet, 3H), 1.77 (narrow multiplet, 3H), 4.30 (q, $J = 7.1$ Hz, 2H), 4.36 (q, $J = 7.1$ Hz, 2H), 4.68 (bd, $J = 7.5$ Hz, 2H), 5.35 (tqq, $J = 7.5$, 1.4, 1.4 Hz, 1H), 6.87 (s, 1H); ^{13}C NMR (100.6 MHz, $CDCl_3$) δ (ppm) 13.9 (q), 14.0 (q), 18.1 (q), 25.8 (q), 62.1 (t), 62.5 (t), 62.6 (t), 117.6 (d), 130.2 (d), 138.9 (s), 140.5 (s), 162.4 (s), 163.6 (s), 164.4 (s); IR (neat) 2983, 1725, 1648, 1466, 1447, 1377, 1348, 1258, 1178, 1066, 1022 cm^{-1} ; MS (EI) m/z 284 (M^+ , 14), 238 (43), 217 (100%); HRMS M^+ 284.1264 (calcd for $C_{14}H_{20}O_6$ M^+ 284.1260).

2-Methyl-2-propenyl 2-chloroacetate. (30.4 mmol scale, 4.30 g, 95%); colorless oil: bp 60–70 °C/5.1 mmHg; 1H NMR (400 MHz, $CDCl_3$) δ (ppm) 1.78 (narrow multiplet, 3H), 4.11 (s, 2H), 4.61 (bs, 2H), 4.98 (narrow multiplet, 1H), 5.02 (narrow multiplet, 1H); ^{13}C NMR (100.6 MHz, $CDCl_3$) δ (ppm) 19.4 (q), 40.8 (d), 69.3 (d), 113.9 (d), 139.1 (s), 167.0 (s); IR (neat) 3085, 2951, 1762, 1660, 1452, 1413, 1312, 1171, 1031, 998 cm^{-1} ; MS (EI) m/z 150 (M^+ , 4.8), 148 (M^+ , 14), 77 (36), 72 (100%); HRMS M^+ 148.0291, 150.0263 (calcd for $C_6H_9ClO_2$ M^+ 148.0291, 150.0262).

1,1-Diethyl 2-(2-methyl-2-propenyl) ethene-1,1,2-tricarboxylate (18). (16 mmol scale, 3.47 g, 80%); colorless oil: 1H NMR (400 MHz, $CDCl_3$) δ (ppm) 1.33 (t, $J = 7.1$ Hz, 3H), 1.34 (t, $J = 7.1$ Hz, 3H), 1.77 (bs, 3H), 4.31 (q, $J = 7.1$ Hz, 2H), 4.36 (q, $J = 7.1$ Hz, 2H), 4.61 (s, 2H), 4.97 (qt, $J = 0.7$, 0.7 Hz, 1H), 5.01 (bs, 1H), 6.91 (s, 1H); ^{13}C NMR (100.6 MHz, $CDCl_3$) δ (ppm) 13.9 (q), 14.0 (q), 19.5 (q), 62.2 (t), 62.6 (t), 69.1 (t), 114.1 (t), 129.8 (d), 139.0 (s), 139.3 (s), 162.3 (s), 163.3 (s), 164.3 (s); IR (neat) 2984, 1728, 1656, 1447, 1375, 1345, 1258, 1179, 1067, 1022 cm^{-1} ; MS (CI) m/z 271 ($[M + 1]^+$); HRMS $[M + 1]^+$ 271.1176 (calcd for $C_{13}H_{19}O_6$ $[M + 1]^+$ 271.1182).

Typical Experimental Procedure (eq 3, Table 1, entry 6). To a solution of **1** (128 mg, 0.5 mmol) in CH_2Cl_2 (2 mL) was $TiCl_4$ (190 mg, 110 μ L, 0.1 mmol). The mixture was stirred at room temperature for 17 h. The reaction mixture was quenched by water and then saturated aqueous $NaHCO_3$. The mixture was extracted with dichloromethane, and the organic phase was dried (Na_2SO_4) and evaporated in vacuo to give **2a** (134 mg, 90%).

Diethyl 2-(trans-4-(chloromethyl)-2-oxotetrahydrofuran-3-yl)malonate (2a). Colorless oil: 1H NMR (400 MHz, $CDCl_3$) δ (ppm) 1.29 (t, $J = 7.1$ Hz, 3H), 1.32 (t, $J = 7.1$ Hz, 3H), 3.09 (dd, $J = 8.4$, 4.1, 1H), 3.20 (dddd, $J = 8.7$, 8.4, 7.1, 6.2, 4.0 Hz, 1H), 3.66 (dd, $J = 11.4$, 6.2 Hz, 1H), 3.72 (dd, $J = 11.4$, 4.0 Hz, 1H), 4.06 (d, $J = 4.1$ Hz, 1H), 4.20 (dd, $J = 9.2$, 7.1 Hz, 1H), 4.21–4.33 (m, 4H), 4.55 (dd, $J = 9.2$, 8.7 Hz, 1H); Selected NOEs are between δ 3.09 (H-3) and δ 3.66, 3.72 (CH_2Cl) and between δ 3.20 (H-4) and δ 4.06 ($CH(CO_2Et)_2$), 4.55 (H-5b); ^{13}C NMR (100.6 MHz, $CDCl_3$) δ (ppm) 13.97 (q), 14.01 (q), 39.3 (d), 42.0 (d), 45.5 (t), 50.9 (d), 62.31 (t), 62.32 (t), 69.5 (t), 167.3 (s), 167.8 (s), 175.8 (s); Selected HMBC correlations are between δ 3.09 (H-3) and δ 45.5 (CH_2Cl), 50.9 ($CH(CO_2Et)_2$), 39.3 (C-4), between δ 3.20 (H-4) and δ 42.0 (C-3), and between δ 4.20, 4.55 (H-5a,5b) and δ 45.5 (CH_2Cl), 39.3 (C-4); IR (neat) 2984, 1777, 1734, 1446, 1393, 1373, 1256, 1183, 1096, 1028 cm^{-1} ; MS (EI) m/z 294 (M^+ , 36%), 292 (M^+ , 100%); HRMS M^+ 292.0720, 294.0706 (calcd for $C_{12}H_{17}ClO_6$ 292.0714, 294.0684).

Diethyl 2-(trans-4-(bromomethyl)-2-oxotetrahydrofuran-3-yl)malonate (2b). (Table 1, entry 3, 1 mmol scale, 193 mg, 57%); colorless oil: 1H NMR (400 MHz, $CDCl_3$) δ (ppm) 1.29 (t, $J = 7.1$ Hz, 3H), 1.32 (t, $J = 7.1$ Hz, 3H), 3.07 (dd, $J = 8.6$, 4.2, 1H), 3.17 (dddd, $J = 8.6$, 8.5, 7.3, 6.8, 3.8 Hz, 1H), 3.51 (dd, $J = 10.6$, 6.8 Hz, 1H), 3.60 (dd, $J = 10.6$, 3.8 Hz, 1H), 4.05 (d, $J = 4.0$ Hz, 1H), 4.15 (dd, $J = 9.3$, 7.3 Hz, 1H), 4.20–4.33 (m, 4H), 4.54 (dd, $J = 9.3$, 8.5 Hz, 1H); Selected NOEs are between δ 3.07 (H-3) and δ 3.51, 3.60 (CH_2Br), between δ 3.17 (H-4) and δ 4.05 ($CH(CO_2Et)_2$), 4.54 (H-5b), and between δ 4.15 (H-5a) and δ 3.51, 3.60 (CH_2Br); ^{13}C NMR (100.6 MHz, $CDCl_3$) δ (ppm) 13.9 (q), 14.0 (q), 34.5 (t), 39.0 (d), 43.4 (d), 50.8 (d), 62.3 (t \times 2), 70.6 (t), 167.2 (s), 167.7 (s), 175.7 (s); Selected HMBC correlations are between δ 3.07 (H-3) and δ 34.5 (CH_2Br), 50.8 ($CH(CO_2Et)_2$), 39.0 (C-4), between δ 3.51, 3.60 (CH_2Br) and δ 43.4 (C-3), 39.0 (C-4), and between δ 4.15, 4.54 (H-5a,b) and δ 34.5 (CH_2Br), 39.0 (C-4); IR (neat) 2983, 1779, 1740, 1475, 1446, 1391, 1373, 1234, 1183, 1029 cm^{-1} ; MS (EI) m/z 338 (M^+ , 100%), 336 (M^+ , 100%); HRMS M^+ 336.0204, 338.0175 (calcd for $C_{12}H_{17}BrO_6$ 336.0209, 338.0188).

3: (2 equiv of ZnI_2 , rt, 0.5 mmol scale, 81 mg, 59%); colorless oil; 1H NMR (400 MHz, $CDCl_3$) δ (ppm) 1.28 (t, $J = 7.1$ Hz, 3H), 1.30 (t, $J = 7.1$ Hz, 3H), 3.33 (bs, 1H), 3.96 (d, $J = 4.2$ Hz, 1H), 4.21–4.30 (m, 4H), 4.699 (ddd, $J = 5.9$, 1.3, 1.3 Hz, 1H), 4.702 (ddd, $J = 5.9$, 1.3, 1.3 Hz, 1H), 4.76 (d, $J = 4.2$ Hz, 1H), 5.27 (dddd, $J = 10.4$, 1.2, 1.2 Hz, 1H), 5.35 (dddd, $J = 17.2$, 1.5, 1.5, 1.5 Hz, 1H), 5.91 (dddd, $J = 17.2$, 10.4, 5.9, 5.9 Hz, 1H); ^{13}C NMR (100.6 MHz, $CDCl_3$) δ (ppm) 14.00 (q), 14.04 (q), 55.2 (d), 62.0 (t), 62.1 (t), 66.7 (t), 69.7 (d), 119.3 (t), 131.3 (d), 167.0 (s), 167.2 (s), 171.5 (s); IR (neat) 3501, 2986, 1739, 1651, 1466, 1448, 1372, 1260, 1177, 1031 cm^{-1} ; MS (EI) m/z 275 ($[M + 1]^+$, 14), 201 (50), 189 (100%); HRMS $[M + 1]^+$ 275.1129 (calcd for $C_{12}H_{19}O_7$ $[M + 1]^+$ 275.1131). Anal. Calcd for $C_{12}H_{18}O_7$: C, 52.55; H, 6.62. Found: C, 52.26; H, 6.80.

4: (2 equiv of $TiCl_4$, -40 °C, 0.5 mmol scale, 113 mg, 77%); compound **4** is unstable to column chromatography (SiO_2) and partial decomposition of **4** to starting material **1** was observed; colorless oil;

¹H NMR (400 MHz, CDCl₃) δ (ppm) 1.26 (t, *J* = 7.1 Hz, 3H), 1.31 (t, *J* = 7.1 Hz, 3H), 4.01 (d, *J* = 10.3 Hz, 1H), 4.17–4.31 (m, 4H), 4.700 (ddd, *J* = 5.8, 1.2, 1.2 Hz, 1H), 4.703 (ddd, *J* = 5.8, 1.2, 1.2 Hz, 1H), 4.82 (d, *J* = 10.3 Hz, 1H), 5.29 (dddd, *J* = 10.6, 1.2, 1.2, 1.2 Hz, 1H), 5.39 (dddd, *J* = 17.2, 1.5, 1.5, 1.5 Hz, 1H), 5.93 (dddd, *J* = 17.2, 10.6, 5.8, 5.8 Hz, 1H); ¹³C NMR (100.6 MHz, CDCl₃) δ (ppm) 14.0 (q), 14.1 (q), 52.7 (d), 56.4 (d), 62.4 (t), 62.5 (t), 66.9 (t), 119.2 (t), 131.0 (d), 165.6 (s), 166.0 (s), 167.5 (s); IR (neat) 2985, 1741, 1650, 1447, 1306, 1166, 1096, 1029 cm⁻¹; MS (EI) *m/z* 294 (M⁺, 36), 292 (100%); HRMS M⁺ 292.0717, 294.0706 (calcd for C₁₂H₁₇ClO₆ M⁺ 292.0714, 294.0684).

Diethyl 2-(trans-4-(1-chloroethyl)-2-oxotetrahydrofuran-3-yl)malonate (7a). (1 equiv of FeCl₃, 1.05 mmol scale, 285 mg, 80%); including a small amount of impurity, possibly containing ene adduct; colorless oil: ¹H NMR (400 MHz, CDCl₃) δ (ppm) 1.28 (t, *J* = 7.1 Hz, 3H), 1.32 (t, *J* = 7.1 Hz, 3H), 1.49 (d, *J* = 6.8 Hz, 3H), 3.09 (dddd, *J* = 9.0, 8.0, 6.8, 3.1 Hz, 1H), 3.19 (dd, *J* = 8.0, 3.9 Hz, 1H), 4.07 (d, *J* = 3.9 Hz, 1H), 4.19–4.32 (m, SH), 4.37 (dd, *J* = 9.2, 6.8 Hz, 1H), 4.48 (dd, *J* = 9.2, 9.0 Hz, 1H); Selected NOEs are between δ 3.19 (H-3) and δ 1.49 (CHCH₃Cl), 4.19–4.32 (CHCH₃Cl, overlapped), between δ 3.09 (H-4) and δ 4.07 (CH(CO₂Et)₂), 4.48 (H-5b); ¹³C NMR (100.6 MHz, CDCl₃) δ (ppm) 14.0 (q), 14.1 (q), 23.0 (q), 42.4 (d), 44.1 (d), 51.0 (d), 58.7 (d), 62.30 (t), 62.33 (t), 67.1 (t), 167.5 (s), 168.0 (s), 176.1 (s); Selected HMBC correlations are between δ 3.19 (H-3) and δ 51.0 CH(CO₂Et)₂, 44.1 (C-4), between δ 3.09 (H-4) and δ 42.4 (C-3), 51.0 (CH(CO₂Et)₂), 58.7 (CHCH₃Cl), 67.1 (C-5), and between δ 4.37, 4.48 (H-5a,b) and δ 58.7 (CHCH₃Cl), 44.1 (C-4); IR (neat) 2984, 1777, 1733, 1467, 1446, 1373, 1265, 1182, 1033 cm⁻¹; MS (CI) *m/z* 309 ([M + 1]⁺, 36%), 307 ([M + 1]⁺, 100%); HRMS [M + 1]⁺ 307.0954, 309.0949 (calcd for C₁₃H₂₀ClO₆ 307.0948, 309.0919).

Dimethyl 2-(trans-4-(1-chloroethyl)-2-oxotetrahydrofuran-3-yl)malonate (7b). (eq 4, 0.54 mmol scale, 78 mg, 52%); pale yellow oil: ¹H NMR (400 MHz, CDCl₃) δ (ppm) 1.50 (d, *J* = 6.8 Hz, 3H), 3.07 (dddd, *J* = 8.9, 8.1, 6.8, 3.2 Hz, 1H), 3.20 (dd, *J* = 8.1, 3.9 Hz, 1H), 3.78 (s, 3H), 3.82 (s, 3H), 4.11 (d, *J* = 3.9 Hz, 1H), 4.27 (qd, *J* = 6.8, 3.2 Hz, 1H), 4.36 (dd, *J* = 9.1, 6.8 Hz, 1H), 4.48 (dd, *J* = 9.1, 8.9 Hz, 1H); Selected NOEs are between δ 3.20 (H-3) and δ 1.50 (CHCH₃Cl), 4.27 (CHCH₃Cl), between δ 3.07 (H-4) and δ 4.11 (CH(CO₂Me)₂), 4.48 (H-5b); ¹³C NMR (100.6 MHz, CDCl₃) δ (ppm) 23.0 (q), 42.4 (d), 44.2 (d), 50.7 (d), 53.1 (q), 53.2 (q), 58.6 (d), 67.2 (t), 167.9 (s), 168.4 (s), 175.9 (s); Selected HMBC correlations are between δ 3.20 (H-3) and δ 58.6 (CHCH₃Cl), 44.2 (C-4), between δ 3.07 (H-4) and δ 42.4 (C-3), and between δ 4.36, 4.48 (H-5a,b) and δ 58.6 (CHCH₃Cl); IR (neat) 2957, 1779, 1742, 1436, 1359, 1197, 1163, 1035 cm⁻¹; MS (EI) *m/z* 281 ([M + 1]⁺, 6.9), 279 ([M + 1]⁺, 22), 85 (93), 83 (100%); HRMS M⁺ 278.0556 (calcd for C₁₁H₁₅ClO₆ 278.0557).

Preparation of Substrates 8a–c. To a solution of 1,1-diethyl 2-hydrogen ethenetricarboxylate (649 mg, 3 mmol) (prepared from 1,1-diethyl 2-*tert*-butyl ethenetricarboxylate upon treatment with CF₃CO₂H) in THF (4.1 mL) were added *N*-allylmethylamine (0.29 mL, 213 mg, 3 mmol), Et₃N (0.42 mL, 304 mg, 3 mmol), HOBT (1-hydroxybenzotriazole) (811 mg, 6 mmol) and EDCI (1-[3-(dimethylamino)propyl]-3-ethylcarbodiimide hydrochloride) (598 mg, 3.1 mmol) at 0 °C. The reaction mixture was stirred for 1 h at 0 °C and was allowed to warm to room temperature and stirred overnight. The reaction mixture was concentrated under reduced pressure, and the residue was diluted with CH₂Cl₂. The organic phase was washed with saturated aqueous NaHCO₃ solution, 2 M aqueous citric acid, saturated aqueous NaHCO₃ and water, dried (Na₂SO₄), and evaporated in vacuo. The residue was purified by column chromatography over silica gel eluting with hexane–ether (1:3) to give **8a** (718 mg, 89%).

8a: pale yellow oil; ¹H NMR (400 MHz, CDCl₃) (2 rotamers, ratio 1.2:1) δ (ppm) 1.31 (t, *J* = 7.1, 3H × 0.55, major rotamer) 1.320 (t, *J* = 7.1 Hz, 3H × 0.45, minor rotamer), 1.323 (t, *J* = 7.1 Hz, 3H × 0.45), 1.33 (t, *J* = 7.1 Hz, 3H × 0.55), 2.98 (s, 3H × 0.55), 3.00 (s, 3H × 0.45), 3.95 (ddd, *J* = 5.1, 1.6, 1.6 Hz, 2H × 0.55), 4.04 (ddd, *J* = 6.0, 1.4, 1.4, 2H × 0.45), 4.26–4.37 (m, 4H), 5.19–5.29 (m, 2H),

5.70–5.84 (m, 1H), 7.27 (s, 1H × 0.55), 7.34 (s, 1H × 0.45); ¹³C NMR (100.6 MHz, CDCl₃) δ (ppm) 14.0 (q), 14.05 (q), 14.08 (q), 33.3 (q), 35.0 (q), 49.8 (t), 52.7 (t), 61.87 (t), 61.90 (t), 62.2 (t), 118.0 (t), 118.3 (t), 132.0 (d), 132.1 (d), 134.2 (d), 134.4 (s), 134.8 (d), 135.0 (s), 163.07 (s), 163.11 (s), 163.9 (s), 164.3 (s), 164.5 (s), 164.6 (s); IR (neat) 2986, 1734, 1657, 1468, 1448, 1408, 1375, 1257, 1069, 1023 cm⁻¹; MS (EI) *m/z* 269 (M⁺, 17), 224 (36), 200 (86), 154 (100%); HRMS 269.1267 (calcd for C₁₃H₁₉NO₅ M⁺ 269.1263).

8b: (3 mmol scale, 523 mg, 59%); colorless oil; ¹H NMR (400 MHz, CDCl₃) δ (ppm) 1.31 (t, *J* = 7.1, 3H) 1.32 (t, *J* = 7.1 Hz, 3H), 3.93 (ddd, *J* = 5.1, 1.7, 1.7 Hz, 2H), 4.03 (ddd, *J* = 6.0, 1.3, 1.3 Hz, 2H), 4.29 (q, *J* = 7.1 Hz, 2H), 4.33 (q, *J* = 7.1 Hz, 2H), 5.16–5.28 (m, 4H), 5.71–5.83 (m, 2H), 7.27 (s, 1H); ¹³C NMR (100.6 MHz, CDCl₃) δ (ppm) 13.9 (q), 14.0 (q), 47.7 (t), 49.6 (t), 61.8 (t), 62.2 (t), 117.9 (t), 118.2 (t), 132.2 (d), 132.3 (d), 134.2 (d), 135.1 (s), 163.0 (s), 164.0 (s), 164.5 (s); IR (neat) 2984, 1733, 1655, 1466, 1445, 1417, 1374, 1256, 1206, 1069 cm⁻¹; MS (EI) *m/z* 295 (M⁺); HRMS 295.1422 (calcd for C₁₅H₂₁NO₅ M⁺ 295.1420).

N-Allylpropylamine was prepared by reaction of propylamine with allylbromide in ethanol according to the literature procedure.²⁴

8c: (3 mmol scale, 741 mg, 83%); colorless oil; ¹H NMR (400 MHz, CDCl₃) (2 rotamers, ratio 1:1) δ (ppm) 0.90 (t, *J* = 7.2, 3H × 0.5), 0.92 (t, *J* = 7.1 Hz, 3H × 0.5), 1.29–1.34 (m, 6H), 1.54–1.66 (m, 2H), 3.26 (dd, *J* = 7.6, 7.6 Hz, 2H × 0.5), 3.21–3.36 (m, 2H × 0.5), 3.94 (ddd, *J* = 4.9, 1.6, 1.6 Hz, 2H × 0.5), 4.03 (ddd, *J* = 6.0, 1.4, 1.4 Hz, 2H × 0.5), 4.26–4.36 (m, 4H), 5.16–5.27 (m, 2H), 5.72–5.85 (m, 1H), 7.26 (s, 1H × 0.5), 7.34 (s, 1H × 0.5); ¹³C NMR (100.6 MHz, CDCl₃) δ (ppm) 11.2 (q), 11.4 (q), 14.0 (q), 14.1 (q), 20.7 (t), 22.2 (t), 47.6 (t), 47.9 (t), 49.4 (t), 50.7 (t), 61.9 (t), 62.17 (t), 62.23 (t), 117.7 (t), 117.8 (t), 132.6 (d), 132.7 (d), 134.2 (d), 134.6 (d), 134.7 (s), 135.0 (s), 163.1 (s), 163.2 (s), 163.7 (s), 164.1 (s), 164.7 (s); IR (neat) 2984, 1731, 1650, 1466, 1375, 1257, 1212, 1069 cm⁻¹; MS (EI) *m/z* 297 (M⁺, 0.5), 273 (4.7), 257 (70), 227 (75), 183 (74), 160 (100%); HRMS 297.1576 (calcd for C₁₅H₂₃NO₅ M⁺ 297.1576).

Typical Experimental Procedure (eq 5, Table 2, entry 1). To a solution of **8a** (135 mg, 0.5 mmol) in CH₂Cl₂ (1 mL) was TiCl₄ (95 mg, 55 μL, 0.5 mmol). The mixture was stirred at room temperature for 17 h. The reaction mixture was quenched by water and then saturated aqueous NaHCO₃. The mixture was extracted with dichloromethane, and the organic phase was dried (Na₂SO₄), and evaporated in vacuo. The residue was purified by column chromatography over silica gel with hexane–ether (1:4) as eluent to give **9a** (150 mg, 98%).

Diethyl 2-(trans-4-(chloromethyl)-1-methyl-2-oxopyrrolidin-3-yl)malonate (9a). Colorless oil: ¹H NMR (400 MHz, CDCl₃) δ (ppm) 1.26 (t, *J* = 7.1 Hz, 3H), 1.31 (t, *J* = 7.1 Hz, 3H), 2.87 (s, 3H), 2.89–2.99 (m, 2H), 3.29 (dd, *J* = 9.8, 5.2 Hz, 1H), 3.56 (dd, *J* = 9.8, 9.8 Hz, 1H), 3.58 (dd, *J* = 11.0, 6.8 Hz, 1H), 3.72 (dd, *J* = 11.0, 3.9 Hz, 1H), 4.05 (d, *J* = 4.0 Hz, 1H), 4.13–4.30 (m, 4H); ¹³C NMR (100.6 MHz, CDCl₃) δ (ppm) 14.0 (q), 14.1 (q), 29.9 (q), 36.1 (d), 44.8 (d), 47.5 (t), 51.3 (d), 51.7 (t), 61.8 (t), 61.9 (t), 167.9 (s), 168.6 (s), 172.2 (s); Selected HMBC correlations are between δ 4.05 (CH(CO₂Et)₂) and δ 44.8 (C-3), 36.1 (C-4), between δ 3.58, 3.72 (CH₂Cl) and δ 36.1 (C-4), 44.8 (C-3), and between δ 3.29, 3.56 (H-5) and δ 47.5 (CH₂Cl), 36.1 (C-4); ¹H NMR (400 MHz, C₆D₆) δ (ppm) 0.863 (t, *J* = 7.1 Hz, 3H), 0.912 (t, *J* = 7.1 Hz, 3H), 2.45 (d, *J* = 0.7 Hz, 3H), 2.59 (dd, *J* = 9.6, 5.8 Hz, 1H), 2.73 (dd, *J* = 7.5, 4.5 Hz, 1H), 2.85 (dddd, *J* = 9.1, 8.2, 7.5, 5.8, 3.8 Hz, 1H), 2.96 (dd, *J* = 10.1, 8.2 Hz, 1H), 3.00 (dd, *J* = 9.6, 9.1 Hz, 1H), 3.26 (dd, *J* = 10.1, 3.8 Hz, 1H), 3.80–3.97 (m, 4H), 4.21 (d, *J* = 4.5 Hz, 1H); Selected NOEs are between δ 2.73 (H-3) and δ 2.96, 3.26 (CH₂Cl) and between δ 2.85 (H-4) and δ 4.21 (CH(CO₂Et)₂); ¹³C NMR (100.6 MHz, C₆D₆) δ (ppm) 13.8 (q), 13.9 (q), 29.3 (q), 36.3 (d), 36.8 (t), 46.3 (d), 51.6 (d), 52.4 (t), 61.5 (t), 61.6 (t), 168.0 (s), 168.7 (s), 171.6 (s); IR (neat) 2986, 2942, 1738, 1688, 1504, 1448, 1375, 1272, 1178, 1100, 1033 cm⁻¹; MS (EI) *m/z* 307 (M⁺, 29), 305 (M⁺, 80), 260 (43), 256 (100%); HRMS M⁺ 305.1037, 307.1010 (calcd for C₁₃H₂₀ClNO₅ 305.1030, 307.1001).

Diethyl 2-(trans-4-(bromomethyl)-1-methyl-2-oxopyrrolidin-3-yl)malonate (9b). (Table 2, entry 8, 0.5 mmol scale, 121 mg, 69%); pale yellow oil: ¹H NMR (400 MHz, CDCl₃) δ (ppm) 1.26

(t, $J = 7.1$ Hz, 3H), 1.31 (t, $J = 7.1$ Hz, 3H), 2.88 (s, 3H), 2.87–2.98 (m, 2H), 3.26 (dd, $J = 9.9, 5.4$ Hz, 1H), 3.45 (dd, $J = 10.3, 7.3$ Hz, 1H), 3.57 (dd, $J = 9.9, 8.9$ Hz, 1H), 3.61 (dd, $J = 10.3, 3.8$ Hz, 1H), 4.05 (d, $J = 4.0$ Hz, 1H), 4.15–4.29 (m, 4H); ^{13}C NMR (100.6 MHz, CDCl_3) δ (ppm) 14.08 (q), 14.12 (q), 29.9 (q), 35.9 (d), 37.0 (t), 46.2 (d), 51.3 (d), 52.9 (t), 61.9 (t), 62.0 (t), 167.9 (s), 168.7 (s), 172.2 (s); ^1H NMR (400 MHz, C_6D_6) δ (ppm) 0.857 (t, $J = 7.1$ Hz, 3H), 0.910 (t, $J = 7.1$ Hz, 3H), 2.45 (d, $J = 0.7$ Hz, 3H), 2.61 (dd, $J = 9.9, 5.9$ Hz, 1H), 2.74 (dd, $J = 7.3, 4.7$ Hz, 1H), 2.86 (dddd, $J = 9.2, 8.2, 7.3, 5.9, 3.8$ Hz, 1H), 2.99 (dd, $J = 10.1, 8.2$ Hz, 1H), 3.02 (dd, $J = 9.9, 9.2$ Hz, 1H), 3.28 (dd, $J = 10.1, 3.8$ Hz, 1H), 3.80–3.97 (m, 4H), 4.22 (d, $J = 4.7$ Hz, 1H); Selected NOEs are between δ 2.74 (H-3) and δ 2.99, 3.28 (CH_2Br) and between δ 2.86 (H-4) and δ 4.22 ($\text{CH}(\text{CO}_2\text{Et})_2$); ^{13}C NMR (100.6 MHz, C_6D_6) δ (ppm) 13.8 (q), 13.9 (q), 29.3 (q), 36.4 (d), 36.9 (t), 46.4 (d), 51.7 (d), 52.4 (t), 61.5 (t), 61.6 (t), 168.1 (s), 168.7 (s), 171.5 (s); Selected HMBC correlations are between δ 2.74 (H-3) and δ 51.7 ($\text{CH}(\text{CO}_2\text{Et})_2$), 36.4 (C-4), between δ 2.61, 3.02 (H-5) and δ 36.9 (CH_2Br), between δ 4.22 ($\text{CH}(\text{CO}_2\text{Et})_2$) and δ 46.4 (C-3), 36.4 (C-4), and between δ 2.99, 3.28 (CH_2Br) and δ 52.4 (C-5), 46.4 (C-3); IR (neat) 2984, 2940, 1734, 1698, 1502, 1446, 1373, 1270, 1178, 1035 cm^{-1} ; MS (EI) m/z 351 (M^+ , 70), 349 (M^+ , 70), 306 (36), 304 (28), 270 (51), 256 (100%); HRMS M^+ 349.0516, 351.0496 (calcd for $\text{C}_{13}\text{H}_{20}\text{BrNO}_5$, 349.0525, 351.0504).

Diethyl 2-(trans-4-(iodomethyl)-1-methyl-2-oxopyrrolidin-3-yl)malonate (9c). (Table 2, entry 11, 0.5 mmol scale, 145 mg, 73%); colorless oil: ^1H NMR (400 MHz, CDCl_3) δ (ppm) 1.26 (t, $J = 7.1$ Hz, 3H), 1.31 (t, $J = 7.1$ Hz, 3H), 2.71 (dddd, $J = 8.8, 8.1, 7.2, 5.8, 3.7$ Hz, 1H), 2.79 (dd, $J = 7.2, 4.4$ Hz, 1H), 2.84 (d, $J = 0.7$ Hz, 3H), 3.12 (dd, $J = 9.8, 5.8$ Hz, 1H), 3.22 (dd, $J = 10.1, 8.1$ Hz, 1H), 3.43 (dd, $J = 10.1, 3.7$ Hz, 1H), 3.55 (dd, $J = 9.8, 8.8$ Hz, 1H), 4.03 (d, $J = 4.4$ Hz, 1H), 4.13–4.31 (m, 4H); Selected NOEs are between δ 2.79 (H-3) and δ 3.22, 3.43 (CH_2I) and between δ 2.71 (H-4) and δ 4.03 ($\text{CH}(\text{CO}_2\text{Et})_2$), 3.55 (H-5b); ^{13}C NMR (100.6 MHz, CDCl_3) δ (ppm) 11.7 (t), 14.07 (q), 14.13 (q), 29.9 (q), 35.9 (d), 48.3 (d), 51.1 (d), 55.1 (t), 61.8 (t), 62.0 (t), 167.9 (s), 168.6 (s), 172.4 (s); Selected HMBC correlations are between δ 2.79 (H-3) and δ 51.13 ($\text{CH}(\text{CO}_2\text{Et})_2$), 35.9 (C-4), 11.7 (CH_2I), between δ 3.12, 3.55 (H-5a,b) and δ 35.9 (C-4), 11.7 (CH_2I), between δ 4.03 ($\text{CH}(\text{CO}_2\text{Et})_2$) and δ 48.3 (C-3), 35.9 (C-4), and between δ 3.22, 3.43 (CH_2I) and δ 55.1 (C-5), 35.9 (C-4), 48.3 (C-3); IR (neat) 2980, 2935, 1730, 1694, 1499, 1443, 1372, 1300, 1267, 1176, 1032 cm^{-1} ; MS (EI) m/z 397 (M^+ , 10), 352 (59), 306 (56), 270 (100%); HRMS M^+ 397.0381 (calcd for $\text{C}_{13}\text{H}_{20}\text{INO}_5$, 397.0386).

Diethyl 2-(trans-1-allyl-4-(chloromethyl)-2-oxopyrrolidin-3-yl)malonate (9d). (Table 2, entry 13, 0.5 mmol scale, 143 mg, 86%); colorless oil: ^1H NMR (400 MHz, CDCl_3) δ (ppm) 1.26 (t, $J = 7.1$ Hz, 3H), 1.31 (t, $J = 7.1$ Hz, 3H), 2.92–2.94 (m, 2H), 3.25 (dd, $J = 9.8, 5.6$ Hz, 1H), 3.55 (dd, $J = 9.8, 9.6$ Hz, 1H), 3.59 (dd, $J = 11.2, 6.6$ Hz, 1H), 3.72 (dd, $J = 11.2, 3.7$ Hz, 1H), 3.90 (dddd, $J = 15.2, 6.0, 1.5, 1.5$ Hz, 1H), 3.93 (dddd, $J = 15.2, 6.0, 1.5, 1.5$ Hz, 1H), 4.07 (d, $J = 3.8$ Hz, 1H), 4.14–4.30 (m, 4H), 5.22 (dddd, $J = 10.3, 1.5, 1.5, 1.5$ Hz, 1H), 5.24 (dddd, $J = 17.0, 1.5, 1.5, 1.5$ Hz, 1H), 5.73 (dddd, $J = 17.0, 10.3, 6.0, 6.0$ Hz, 1H); ^{13}C NMR (100.6 MHz, CDCl_3) δ (ppm) 14.0 (q), 14.1 (q), 36.0 (d), 45.0 (d), 45.3 (t), 47.5 (t), 49.1 (t), 51.3 (d), 61.8 (t), 61.9 (t), 118.3 (t), 131.9 (d), 167.9 (s), 168.6 (s), 171.9 (s); ^1H NMR (400 MHz, C_6D_6) δ (ppm) 0.869 (t, $J = 7.1$ Hz, 3H), 0.907 (t, $J = 7.1$ Hz, 3H), 2.79 (dd, $J = 9.5, 5.7$ Hz, 1H), 2.86 (dd, $J = 7.4, 4.3$ Hz, 1H), 2.91 (dddd, $J = 9.0, 7.6, 7.4, 5.7, 3.8$ Hz, 1H), 3.19 (dd, $J = 9.5, 9.0$ Hz, 1H), 3.20 (dd, $J = 11.0, 7.6$ Hz, 1H), 3.37 (dd, $J = 11.0, 3.8$ Hz, 1H), 3.61 (dd, $J = 15.3, 6.1$ Hz, 1H), 3.81 (dddd, $J = 15.3, 5.7, 1.6, 1.6$ Hz, 1H), 3.80–3.97 (m, 4H), 4.26 (d, $J = 4.3$ Hz, 1H), 4.96 (dddd, $J = 10.2, 1.4, 1.4, 1.4$ Hz, 1H), 5.02 (dddd, $J = 17.2, 1.6, 1.6, 1.6$ Hz, 1H), 5.54 (dddd, $J = 17.2, 10.2, 5.8, 5.8$ Hz, 1H); Selected NOEs are between δ 2.86 (H-3) and δ 3.20, 3.37 (CH_2Cl) and between δ 2.91 (H-4) and δ 4.26 ($\text{CH}(\text{CO}_2\text{Et})_2$); ^{13}C NMR (100.6 MHz, C_6D_6) δ (ppm) 13.9 (q \times 2), 36.5 (d), 45.1 (d), 45.3 (t), 47.5 (t), 48.8 (t), 51.6 (d), 61.5 (t), 61.6 (t), 117.5 (t), 132.6 (d), 168.1 (s), 168.8 (s), 171.4 (s); Selected HMBC correlations are between δ 2.86 (H-3) and δ 51.6 ($\text{CH}(\text{CO}_2\text{Et})_2$), 36.5 (C-4), 47.5 (CH_2Cl), between δ 2.79, 3.19 (H-5)

and δ 36.5 (C-4), 47.5 (CH_2Cl), between δ 4.26 ($\text{CH}(\text{CO}_2\text{Et})_2$) and δ 45.1 (C-3), 36.5 (C-4), and between δ 3.20, 3.37 (CH_2Cl) and δ 48.8 (C-5), 45.1 (C-3), 36.5 (C-4); IR (neat) 2983, 1733, 1694, 1645, 1491, 1450, 1373, 1274, 1176, 1176, 1031 cm^{-1} ; MS (EI) m/z 333 (M^+ , 26), 331 (M^+ , 72), 282 (100), 190 (96%); HRMS M^+ 331.1188, 333.1154 (calcd for $\text{C}_{15}\text{H}_{22}\text{ClNO}_5$, 331.1187, 333.1157).

Diethyl 2-(trans-1-allyl-4-(bromomethyl)-2-oxopyrrolidin-3-yl)malonate (9e). (Table 2, entry 14, 0.5 mmol scale, 128 mg, 71%); pale yellow oil: ^1H NMR (400 MHz, CDCl_3) δ (ppm) 1.27 (t, $J = 7.1$ Hz, 3H), 1.31 (t, $J = 7.1$ Hz, 3H), 2.92–2.99 (m, 2H), 3.22 (dd, $J = 9.8, 5.7$ Hz, 1H), 3.46 (dd, $J = 10.3, 7.0$ Hz, 1H), 3.55 (dd, $J = 9.8, 9.4$ Hz, 1H), 3.61 (dd, $J = 10.3, 3.7$ Hz, 1H), 3.90 (dddd, $J = 15.2, 6.0, 1.2, 1.2$ Hz, 1H), 3.94 (dddd, $J = 15.2, 6.0, 1.4, 1.4$ Hz, 1H), 4.07 (d, $J = 3.8$ Hz, 1H), 4.14–4.30 (m, 4H), 5.22 (dddd, $J = 10.1, 1.3, 1.3, 1.3$ Hz, 1H), 5.25 (dddd, $J = 17.2, 1.5, 1.5, 1.5$ Hz, 1H), 5.73 (dddd, $J = 17.2, 10.1, 6.0, 6.0$ Hz, 1H); ^{13}C NMR (100.6 MHz, CDCl_3) δ (ppm) 14.05 (q), 14.08 (q), 35.8 (d), 37.0 (t), 45.5 (t), 46.3 (d), 50.2 (t), 51.2 (d), 61.8 (t), 62.0 (t), 118.4 (t), 131.9 (d), 167.8 (s), 168.6 (s), 171.9 (s); ^1H NMR (400 MHz, C_6D_6) δ (ppm) 0.862 (t, $J = 7.1$ Hz, 3H), 0.901 (t, $J = 7.1$ Hz, 3H), 2.74 (dd, $J = 9.6, 6.0$ Hz, 1H), 2.83 (dd, $J = 7.7, 4.4$ Hz, 1H), 2.93 (dddd, $J = 8.7, 7.7, 7.7, 6.0, 3.7$ Hz, 1H), 3.04 (dd, $J = 10.2, 7.7$ Hz, 1H), 3.18 (dd, $J = 9.6, 8.7$ Hz, 1H), 3.24 (dd, $J = 10.2, 3.7$ Hz, 1H), 3.60 (dd, $J = 15.4, 6.0$ Hz, 1H), 3.80 (dddd, $J = 15.4, 5.7, 1.6, 1.6$ Hz, 1H), 3.80–3.96 (m, 4H), 4.27 (d, $J = 4.4$ Hz, 1H), 4.96 (dddd, $J = 10.3, 1.4, 1.4, 1.4$ Hz, 1H), 5.00 (dddd, $J = 17.2, 1.6, 1.6, 1.6$ Hz, 1H), 5.54 (dddd, $J = 17.2, 10.3, 6.0, 5.7$ Hz, 1H); Selected NOEs are between δ 2.83 (H-3) and δ 3.04, 3.24 (CH_2Br) and between δ 2.93 (H-4) and δ 4.27 ($\text{CH}(\text{CO}_2\text{Et})_2$), 3.18 (H-5b); ^{13}C NMR (100.6 MHz, C_6D_6) δ (ppm) 13.85 (q), 13.87 (q), 36.3 (d), 36.9 (t), 45.3 (t), 46.4 (d), 49.9 (t), 51.5 (d), 61.5 (t), 61.6 (t), 117.5 (t), 132.6 (d), 168.1 (s), 168.8 (s), 171.4 (s); Selected HMBC correlations are between δ 2.83 (H-3) and δ 51.5 ($\text{CH}(\text{CO}_2\text{Et})_2$), 36.3 (C-4), 36.9 (CH_2Br), between δ 2.74, 3.18 (H-5a,b) and δ 36.3 (C-4), between δ 4.27 ($\text{CH}(\text{CO}_2\text{Et})_2$) and δ 46.4 (C-3), 36.3 (C-4), and between δ 3.04, 3.24 (CH_2Br) and δ 49.9 (C-5), 46.4 (C-3); IR (neat) 2981, 1734, 1696, 1645, 1491, 1448, 1374, 1265, 1033 cm^{-1} ; MS (EI) m/z 377 (M^+ , 53), 375 (M^+ , 53), 332 (41), 330 (38), 296 (56), 282 (100%); HRMS M^+ 375.0689, 377.0665 (calcd for $\text{C}_{15}\text{H}_{22}\text{BrNO}_5$, 375.0681, 377.0661). Anal. Calcd for $\text{C}_{15}\text{H}_{22}\text{BrNO}_5$: C, 47.88; H, 5.89; N, 3.72. Found: C, 48.14; H, 6.00; N, 3.74.

Diethyl 2-(trans-1-allyl-4-(iodomethyl)-2-oxopyrrolidin-3-yl)malonate (9f). (Table 2, entry 16, 0.5 mmol scale, 164 mg, 77%); pale yellow oil: ^1H NMR (400 MHz, CDCl_3) δ (ppm) 1.27 (t, $J = 7.1$ Hz, 3H), 1.31 (t, $J = 7.1$ Hz, 3H), 2.71 (dddd, $J = 8.8, 7.9, 7.5, 6.0, 3.7$ Hz, 1H), 2.84 (dd, $J = 7.5, 4.2$ Hz, 1H), 3.08 (dd, $J = 9.9, 6.0$ Hz, 1H), 3.24 (dd, $J = 10.1, 7.9$ Hz, 1H), 3.42 (dd, $J = 10.1, 3.7$ Hz, 1H), 3.53 (dd, $J = 9.9, 8.8$ Hz, 1H), 3.89 (dd, $J = 15.2, 6.0$ Hz, 1H), 3.94 (dddd, $J = 15.2, 4.5, 1.4, 1.4$ Hz, 1H), 4.05 (d, $J = 4.2$ Hz, 1H), 4.14–4.31 (m, 4H), 5.22 (dddd, $J = 10.1, 1.3, 1.3, 1.3$ Hz, 1H), 5.25 (dddd, $J = 17.2, 1.4, 1.4, 1.4$ Hz, 1H), 5.73 (dddd, $J = 17.2, 10.1, 6.0, 6.0$ Hz, 1H); Selected NOEs are between δ 2.84 (H-3) and δ 3.24, 3.42 (CH_2I), between δ 2.71 (H-4) and δ 4.05 ($\text{CH}(\text{CO}_2\text{Et})_2$), 3.53 (H-5b), and between δ 3.08 (H-5a) and δ 3.24, 3.42 (CH_2I); ^{13}C NMR (100.6 MHz, CDCl_3) δ (ppm) 11.8 (t), 14.07 (q), 14.12 (q), 35.7 (d), 45.5 (t), 48.4 (d), 51.0 (d), 52.4 (t), 61.8 (t), 62.0 (t), 118.5 (t), 131.9 (d), 167.9 (s), 168.6 (s), 172.1 (s); Selected HMBC correlations are between δ 2.84 (H-3) and δ 51.0 ($\text{CH}(\text{CO}_2\text{Et})_2$), 35.7 (C-4), 11.8 (CH_2I), between δ 3.08, 3.53 (H-5a,b) and δ 35.7 (C-4), between δ 4.05 ($\text{CH}(\text{CO}_2\text{Et})_2$) and δ 35.7 (C-4), and between δ 3.24, 3.42 (CH_2I) and δ 52.4 (C-5); IR (neat) 2982, 1731, 1694, 1645, 1489, 1447, 1372, 1270, 1178, 1159, 1033 cm^{-1} ; MS (EI) m/z 423 (M^+ , 21), 378 (23), 296 (100%); HRMS M^+ 423.0548 (calcd for $\text{C}_{15}\text{H}_{22}\text{INO}_5$, 423.0543).

Diethyl 2-(trans-4-(chloromethyl)-1-propyl-2-oxopyrrolidin-3-yl)malonate (9g). (Table 2, entry 18, 0.5 mmol scale, 163 mg, 98%); pale yellow oil: ^1H NMR (400 MHz, CDCl_3) δ (ppm) 0.908 (t, $J = 7.4$ Hz, 3H), 1.26 (t, $J = 7.1$ Hz, 3H), 1.30 (t, $J = 7.1$ Hz, 3H), 1.57 (qt, $J = 7.4, 7.4$ Hz, 2H), 2.91–2.98 (m, 2H), 3.21–3.32 (m, 3H), 3.55–3.61 (m, 2H), 3.72 (dd, $J = 11.0, 3.7$ Hz, 1H), 4.07 (d, $J = 4.0$ Hz, 1H), 4.13–4.29 (m, 4H); ^{13}C NMR (100.6 MHz, CDCl_3) δ

(ppm) 11.3 (q), 14.08 (q), 14.10 (q), 20.3 (t), 36.1 (d), 44.5 (t), 45.2 (d), 47.7 (t), 49.4 (t), 51.3 (d), 61.8 (t), 62.0 (t), 168.0 (s), 168.7 (s), 172.0 (s); $^1\text{H NMR}$ (400 MHz, C_6D_6) δ (ppm) 0.744 (t, $J = 7.3$ Hz, 3H), 0.869 (t, $J = 7.1$ Hz, 3H), 0.904 (t, $J = 7.1$ Hz, 3H), 1.26 (qt, $J = 7.3$, 7.3 Hz, 2H), 2.76 (dd, $J = 9.5$, 5.9 Hz, 1H), 2.84 (dd, $J = 7.3$, 4.4 Hz, 1H), 2.92 (m, 1H), 3.02 (dt, $J = 13.7$, 6.9 Hz, 1H), 3.08–3.23 (m, 3H), 3.41 (dd, $J = 11.1$, 3.9 Hz, 1H), 3.80–3.97 (m, 4H), 4.27 (dd, $J = 4.4$, 1.8 Hz, 1H); Selected NOEs are between δ 2.84 (H-3) and δ 3.08–3.23 (overlapped), 3.41 (CH_2Cl) and between δ 2.92 (H-4) and δ 4.27 ($\text{CH}(\text{CO}_2\text{Et})_2$); $^{13}\text{C NMR}$ (100.6 MHz, C_6D_6) δ (ppm) 11.3 (q), 13.9 (q \times 2), 20.5 (t), 36.6 (d), 44.3 (t), 45.3 (d), 47.7 (t), 49.1 (t), 51.6 (d), 61.4 (t), 61.6 (t), 168.1 (s), 168.8 (s), 171.5 (s); Selected HMBC correlations are between δ 2.84 (H-3) and δ 51.6 ($\text{CH}(\text{CO}_2\text{Et})_2$), 36.6 (C-4), 47.7 (CH_2Cl), between δ 2.76 (H-5a) and δ 36.6 (C-4), 47.7 (CH_2Cl), between δ 4.27 ($\text{CH}(\text{CO}_2\text{Et})_2$) and δ 45.3 (C-3), 36.6 (C-4), and between δ 3.41 (CHHCl) and δ 49.1 (C-5), 45.3 (C-3), 36.6 (C-4); IR (neat) 2970, 1734, 1694, 1493, 1456, 1373, 1274, 1373, 1274, 1178, 1033 cm^{-1} ; MS (EI) m/z 335 (M^+ , 32), 333 (M^+ , 91), 305 (53), 284 (100%); HRMS M^+ 333.1344 (calcd for $\text{C}_{15}\text{H}_{24}\text{ClNO}_5$, 333.1343).

Diethyl 2-(trans-4-(bromomethyl)-1-propyl-2-oxopyrrolidin-3-yl)malonate (9h). (Table 2, entry 20, 0.5 mmol scale, 167 mg, 88%); colorless oil: $^1\text{H NMR}$ (400 MHz, CDCl_3) δ (ppm) 0.910 (t, $J = 7.3$ Hz, 3H), 1.26 (t, $J = 7.1$ Hz, 3H), 1.31 (t, $J = 7.1$ Hz, 3H), 1.57 (qt, $J = 7.3$, 7.3 Hz, 2H), 2.89–2.98 (m, 2H), 3.21–3.32 (m, 3H), 3.45 (dd, $J = 10.3$, 7.1 Hz, 1H), 3.58 (dd, $J = 9.5$, 9.5 Hz, 1H), 3.61 (dd, $J = 10.3$, 3.5 Hz, 1H), 4.06 (d, $J = 4.0$ Hz, 1H), 4.13–4.30 (m, 4H); $^{13}\text{C NMR}$ (100.6 MHz, CDCl_3) δ (ppm) 11.3 (q), 14.07 (q), 14.10 (q), 20.4 (t), 35.9 (d), 37.1 (t), 44.5 (t), 46.5 (d), 50.6 (t), 51.2 (d), 61.8 (t), 61.9 (t), 167.9 (s), 168.7 (s), 172.0 (s); $^1\text{H NMR}$ (400 MHz, C_6D_6) δ (ppm) 0.745 (t, $J = 7.3$ Hz, 3H), 0.864 (t, $J = 7.1$ Hz, 3H), 0.900 (t, $J = 7.1$ Hz, 3H), 1.27 (qt, $J = 7.3$, 7.3 Hz, 2H), 2.71 (dd, $J = 9.6$, 6.0 Hz, 1H), 2.81 (dd, $J = 7.5$, 2.9 Hz, 1H), 2.94 (dddd, $J = 8.6$, 7.9, 7.5, 6.0, 3.7 Hz, 1H), 2.98–3.12 (m, 2H), 3.04 (dd, $J = 10.1$, 7.9 Hz, 1H), 3.14 (dd, $J = 9.6$, 8.6 Hz, 1H), 3.29 (dd, $J = 10.1$, 3.7 Hz, 1H), 3.80–4.00 (m, 4H), 4.28 (d, $J = 4.4$ Hz, 1H); Selected NOEs are between δ 2.81 (H-3) and δ 3.04, 3.29 (CH_2Br) and between δ 2.94 (H-4) and δ 4.28 ($\text{CH}(\text{CO}_2\text{Et})_2$), and between δ 2.71 (H-5a) and δ 3.29 (CHHBr); $^{13}\text{C NMR}$ (100.6 MHz, C_6D_6) δ (ppm) 11.3 (q), 13.86 (q), 13.87 (q), 20.5 (t), 36.4 (d), 37.1 (t), 44.3 (t), 46.6 (d), 50.3 (t), 51.5 (d), 61.5 (t), 61.6 (t), 168.1 (s), 168.8 (s), 171.5 (s); Selected HMBC correlations are between δ 2.81 (H-3) and δ 51.5 ($\text{CH}(\text{CO}_2\text{Et})_2$), 36.4 (C-4), 37.1 (CH_2Br), between δ 2.71 (H-5a) and δ 37.1 (CH_2Br), between δ 4.28 ($\text{CH}(\text{CO}_2\text{Et})_2$) and δ 46.6 (C-3), 36.4 (C-4), and between δ 3.04, 3.29 (CH_2Br) and δ 50.3 (C-5); IR (neat) 2966, 2935, 1732, 1694, 1490, 1453, 1372, 1267, 1176, 1035 cm^{-1} ; MS (EI) m/z 380 ($[\text{M} + 1]^+$, 15), 378 ($[\text{M} + 1]^+$, 16), 85 (84), 83 (100%); HRMS M^+ 377.0838, 379.0823 (calcd for $\text{C}_{15}\text{H}_{24}\text{BrNO}_5$, 377.0838, 379.0817).

Diethyl 2-(trans-4-(iodomethyl)-1-propyl-2-oxopyrrolidin-3-yl)malonate (9i). (Table 2, entry 22, 0.5 mmol scale, 184 mg, 87%); colorless oil: $^1\text{H NMR}$ (400 MHz, CDCl_3) δ (ppm) 0.913 (t, $J = 7.4$ Hz, 3H), 1.26 (t, $J = 7.1$ Hz, 3H), 1.31 (t, $J = 7.1$ Hz, 3H), 1.57 (qt, $J = 7.4$, 7.4 Hz, 2H), 2.70 (dddd, $J = 8.6$, 8.1, 7.3, 5.9, 3.6 Hz, 1H), 2.82 (dd, $J = 7.3$, 4.2 Hz, 1H), 3.11 (dd, $J = 9.9$, 5.9 Hz, 1H), 3.23 (dd, $J = 10.0$, 8.1 Hz, 1H), 3.23–3.32 (m, 2H), 3.43 (dd, $J = 10.0$, 3.6 Hz, 1H), 3.56 (dd, $J = 9.9$, 8.6 Hz, 1H), 4.05 (d, $J = 4.2$ Hz, 1H), 4.13–4.30 (m, 4H); Selected NOEs are between δ 2.82 (H-3) and δ 3.23, 3.43 (CH_2I), between δ 2.70 (H-4) and δ 4.05 ($\text{CH}(\text{CO}_2\text{Et})_2$), 3.56 (H-5b), and between δ 3.11 (H-5a) and δ 3.23, 3.43 (CH_2I); $^{13}\text{C NMR}$ (100.6 MHz, CDCl_3) δ (ppm) 11.3 (q), 11.9 (t), 14.09 (q), 14.13 (q), 20.4 (t), 35.8 (d), 44.6 (t), 48.6 (d), 51.1 (d), 52.9 (t), 61.8 (t), 62.0 (t), 167.9 (s), 168.7 (s), 172.2 (s); Selected HMBC correlations are between δ 2.82 (H-3) and δ 51.1 ($\text{CH}(\text{CO}_2\text{Et})_2$), 35.8 (C-4), 11.9 (CH_2I), between δ 3.11, 3.56 (H-5a,b) and δ 35.8 (C-4), 11.9 (CH_2I), between δ 4.05 ($\text{CH}(\text{CO}_2\text{Et})_2$) and δ 48.6 (C-3), 35.8 (C-4), and between δ 3.23, 3.43 (CH_2I) and δ 52.9 (C-5); IR (neat) 2965, 2934, 1732, 1694, 1489, 1450, 1372, 1269, 1177, 1158, 1033 cm^{-1} ; MS (EI) m/z 426 ($[\text{M} + 1]^+$); HRMS M^+ 425.0706 (calcd for $\text{C}_{15}\text{H}_{24}\text{INO}_5$, 425.0699).

Transformation of 2a to 10. A solution of compound 2a (158 mg, 0.54 mmol), Bu_3SnH (313 mg, 290 μL , 1.08 mmol), and AIBN (17.4 mg, 0.108 mmol) in benzene (3.3 mL) was heated at reflux for 3 h and cooled to room temperature. The reaction mixture was concentrated under reduced pressure. The residue was purified by column chromatography over silica gel with hexane–ether as the eluent to give 10 (137 mg, 98%).

10: colorless oil; $^1\text{H NMR}$ (400 MHz, CDCl_3) δ (ppm) 1.14 (d, $J = 6.4$ Hz, 3H), 1.29 (t, $J = 7.1$ Hz, 3H), 1.31 (t, $J = 7.1$ Hz, 3H), 2.73–2.84 (m, 2H), 3.80 (dd, $J = 8.9$, 8.9 Hz, 1H), 3.90 (d, $J = 4.6$ Hz, 1H), 4.20–4.30 (m, 2H), 4.48 (dd, $J = 8.9$, 7.8 Hz, 1H); $^{13}\text{C NMR}$ (100.6 MHz, CDCl_3) δ (ppm) 14.0 (q), 14.1 (q), 17.4 (q), 33.2 (d), 46.5 (d), 50.6 (d), 62.03 (t), 62.04 (t), 73.1 (t), 167.4 (s), 167.7 (s), 176.6 (s); Selected HMBC correlations are between δ 3.80, 4.48 (H-5) and δ 33.2 (C-4), between δ 4.48 ($\text{CH}(\text{CO}_2\text{Et})_2$) and δ 46.5 (C-3), 33.2 (C-4), and between δ 1.14 (CH_3) and δ 73.1 (C-5), 46.5 (C-3), 33.2 (C-4); IR (neat) 2983, 1777, 1736, 1466, 1391, 1372, 1252, 1176, 1024 cm^{-1} ; MS (CI) m/z 259 ($[\text{M} + 1]^+$); HRMS $[\text{M} + 1]^+$ 259.1183 (calcd for $\text{C}_{12}\text{H}_{19}\text{O}_6$, 259.1182). Anal. Calcd for $\text{C}_{12}\text{H}_{18}\text{O}_6$: C, 55.81; H, 7.02. Found: C, 55.91; H, 7.15.

11: (0.2 mmol scale, 34 mg, 60%); colorless oil; $^1\text{H NMR}$ (400 MHz, CDCl_3) δ (ppm) 1.13 (d, $J = 6.8$ Hz, 3H), 1.26 (t, $J = 7.1$ Hz, 3H), 1.29 (t, $J = 7.1$ Hz, 3H), 2.54 (ddq, $J = 8.5$, 7.9, 6.8, 6.5 Hz, 1H), 2.68 (ddq, $J = 7.9$, 5.0, 0.7 Hz, 1H), 2.85 (d, $J = 0.7$ Hz, 3H), 2.93 (dd, $J = 9.4$, 6.5 Hz, 1H), 3.50 (dd, $J = 9.4$, 8.5 Hz, 1H), 3.90 (d, $J = 5.0$ Hz, 1H), 4.13–4.29 (m, 4H); Selected NOEs are between δ 2.68 (H-3) and δ 1.13 (CH_3), between δ 2.54 (H-4) and δ 3.90 ($\text{CH}(\text{CO}_2\text{Et})_2$), 3.50 (H-5b), and between 2.93 (H-5a) and 1.13 (CH_3); $^{13}\text{C NMR}$ (100.6 MHz, CDCl_3) δ (ppm) 14.05 (q), 14.10 (q), 19.9 (q), 29.5 (d), 29.8 (q), 49.3 (d), 51.4 (d), 55.6 (t), 61.5 (t), 61.6 (t), 168.1 (s), 168.6 (s), 173.3 (s); Selected HMBC correlations are between δ 2.68 (H-3) and δ 51.4 ($\text{CH}(\text{CO}_2\text{Et})_2$), 29.5 (C-4), 19.9 (CH_3), between δ 2.54 (H-4) and δ 55.6 (C-5), 51.4 ($\text{CH}(\text{CO}_2\text{Et})_2$), 49.3 (C-3), 19.9 (CH_3), between δ 2.93, 3.50 (H-5a,b) and δ 29.5 (C-4), 19.9 (CH_3), between δ 3.90 ($\text{CH}(\text{CO}_2\text{Et})_2$) and δ 49.3 (C-3), 29.5 (C-4), and between δ 1.13 (CH_3) and δ 55.6 (C-5), 49.3 (C-3), 29.5 (C-4); IR (neat) 2980, 1733, 1696, 1501, 1444, 1372, 1270, 1157, 1032 cm^{-1} ; MS (EI) m/z 271 (M^+ , 31), 226 (18), 152 (64), 124 (100%); HRMS M^+ 271.1416 (calcd for $\text{C}_{13}\text{H}_{21}\text{NO}_5$, 271.1420). Anal. Calcd for $\text{C}_{13}\text{H}_{21}\text{NO}_5$: C, 57.55; H, 7.80; N, 5.16. Found: C, 57.37; H, 7.83; N, 5.07.

Diethyl 2-(t-4-(chloromethyl)-c-5-methyl-2-oxotetrahydrofuran-r-3-yl)malonate (13). A 1.3:1 (13:7a) mixture (eq 7, 1 equiv of AlCl_3 , 0.5 mmol scale, 80 mg, combined yield 52%); colorless oil: $^1\text{H NMR}$ (400 MHz, CDCl_3) δ (ppm) peaks for 13, 1.27–1.34 (m, 6H), 1.53 (d, $J = 6.2$ Hz, 3H), 2.81 (ddt, $J = 10.1$, 8.2, 4.2 Hz, 1H), 3.29 (dd, $J = 10.1$, 4.0 Hz, 1H), 3.69 (d, $J = 4.2$ Hz, 2H), 4.07 (d, $J = 4.0$ Hz, 1H); Selected NOEs are between δ 3.29 (H-3) and δ 3.69 (CH_2Cl), between δ 2.81 (H-4) and δ 4.07 ($\text{CH}(\text{CO}_2\text{Et})_2$), 1.53 (CH_3), and between δ 4.52 (H-5) and δ 3.69 (CH_2Cl); $^{13}\text{C NMR}$ (100.6 MHz, CDCl_3) δ (ppm) peaks for 13, 13.98 (q), 14.02 (q), 20.1 (q), 42.5 (d), 43.9 (t), 46.4 (d), 50.4 (d), 62.2 (t), 62.3 (t), 77.5 (d), 167.3 (s), 168.0 (s), 174.8 (s); Selected HMBC correlations are between δ 3.29 (H-3) and δ 50.4 ($\text{CH}(\text{CO}_2\text{Et})_2$), 46.4 (C-4), between δ 4.52 (H-5) and δ 43.9 (CH_2Cl), between δ 3.69 (CH_2Cl) and δ 77.5 (C-5), and between δ 1.53 (CH_3) and δ 77.5 (C-5), 46.4 (C-4); IR (neat) 2984, 1779–1732, 1466, 1446, 1373, 1197, 1097, 1031 cm^{-1} ; MS (CI) m/z 309 ($[\text{M} + \text{H}]^+$, 49%), 307 ($[\text{M} + \text{H}]^+$, 100%); HRMS M^+ 307.0941, 309.0924 (calcd for $\text{C}_{13}\text{H}_{20}\text{ClO}_6$, 307.0948, 309.0919).

Diethyl 2-(trans-4-(2-chloropropan-2-yl)-2-oxotetrahydrofuran-3-yl)malonate (15). (eq 8, TiCl_4 , 0.5 mmol scale, 27 mg, isolated yield 17%); pale yellow oil: $^1\text{H NMR}$ (400 MHz, CDCl_3) δ (ppm) 1.29 (t, $J = 7.1$ Hz, 3H), 1.32 (t, $J = 7.1$ Hz, 3H), 1.54 (s, 3H), 1.56 (s, 3H), 2.78 (ddd, $J = 8.8$, 5.7, 4.6 Hz, 1H), 3.18 (dd, $J = 5.7$, 4.1 Hz, 1H), 4.00 (d, $J = 4.1$ Hz, 1H), 4.15–4.33 (m, 4H), 4.47 (dd, $J = 9.3$, 4.6 Hz, 1H), 4.57 (dd, $J = 9.3$, 8.8 Hz, 1H); Selected NOEs are between δ 3.18 (H-3) and δ 1.54, 1.56 ($\text{C}(\text{CH}_3)_2\text{Cl}$) and between δ 2.78 (H-4) and δ 4.00 ($\text{CH}(\text{CO}_2\text{Et})_2$), 4.57 (H-5b); $^{13}\text{C NMR}$ (100.6 MHz, CDCl_3) δ (ppm) 14.0 (q), 29.9 (q), 30.2 (q), 42.1 (d), 49.4 (d), 52.9 (d), 62.3 (t), 62.4 (t), 69.1 (t), 70.6 (s), 167.4 (s), 167.8 (s), 176.2 (s); Selected HMBC correlations are between δ 3.18 (H-3) and

δ 70.6 (C(CH₃)₂Cl), 52.9 (CH(CO₂Et)₂), 49.4 (C-4) and between δ 4.47, 4.57 (H-5a,5b) and δ 70.6 (C(CH₃)₂Cl), 176.2 (C-2); IR (neat) 2984, 1778, 1735, 1467, 1393, 1374, 1182, 1034 cm⁻¹; MS (EI) *m/z* 322 (M⁺, 2.7), 320 (M⁺, 7.5), 285 (100), 275 (41), 243 (74%); HRMS M⁺ 320.1027, 322.1005 (calcd for C₁₄H₂₁ClO₆ 320.1027, 322.0997).

Diethyl 2-(trans-4-(propen-2-yl)-2-oxotetrahydrofuran-3-yl)malonate (16). (eq 9, AlCl₃, 0.5 mmol scale, 27 mg, isolated yield 19%); pale yellow oil: ¹H NMR (400 MHz, CDCl₃) δ (ppm) 1.276 (t, *J* = 7.1 Hz, 3H), 1.280 (t, *J* = 7.1 Hz, 3H), 1.75 (dd, *J* = 1.5, 0.7 Hz, 3H), 3.25 (dd, *J* = 10.8, 5.5 Hz, 1H), 3.50 (ddd, *J* = 10.8, 9.3, 8.9 Hz, 1H), 3.84 (d, *J* = 5.5 Hz, 1H), 4.00 (dd, *J* = 9.3, 9.3 Hz, 1H), 4.14–4.25 (m, 4H), 4.46 (dd, *J* = 8.9, 8.9 Hz, 1H), 4.89 (qd, *J* = 0.7, 0.7 Hz, 1H), 4.91 (qd, *J* = 1.5, 1.5 Hz, 1H); Selected NOEs are between δ 3.25 (H-3) and δ 4.89 (=CHH), 1.75 (C(CH₃)=CH₂), between δ 3.50 (H-4) and δ 3.84 (CH(CO₂Et)₂), 4.46 (H-5b), and between δ 4.00 (H-5a) and δ 1.75 (C(CH₃)=CH₂); ¹³C NMR (100.6 MHz, CDCl₃) δ (ppm) 14.0 (q), 14.1 (q), 18.6 (q), 42.1 (d), 45.9 (d), 50.4 (d), 61.9 (t), 62.0 (t), 70.0 (t), 115.1 (t), 140.5 (s), 167.3 (s), 167.4 (s), 176.0 (s); Selected HMBC correlations are between δ 3.25 (H-3) and δ 50.4 (CH(CO₂Et)₂), 45.9 (C-4), between δ 3.50 (H-4) and δ 42.1 (C-3), and between δ 4.00, 4.46 (H-5a,5b) and δ 45.9 (C-4); IR (neat) 2982, 1779, 1734, 1647, 1372, 1263, 1163, 1032 cm⁻¹; MS (EI) *m/z* 285 ([M + 1]⁺, 54), 239 (37), 85 (98), 83 (100%); HRMS M⁺ 284.1259 (calcd for C₁₄H₂₀O₆ 284.1260).

Diethyl 2-(t-5-chloro-5-methyl-2-oxo-2H-tetrahydropyran-3-yl)malonate (19). (eq 10, 0.5 mmol scale, 108 mg, 70%); colorless oil: ¹H NMR (400 MHz, CDCl₃) δ (ppm) 1.29 (t, *J* = 7.1 Hz, 3H), 1.31 (t, *J* = 7.1 Hz, 3H), 1.67 (s, 3H), 2.20 (ddd, *J* = 13.9, 7.1, 3.1 Hz, 1H), 2.34 (dd, *J* = 13.9, 11.7 Hz, 1H), 3.45 (ddd, *J* = 11.7, 7.1, 4.6 Hz, 1H), 4.19 (d, *J* = 4.6 Hz, 1H), 4.17–4.29 (m, 4H), 4.33 (dd, *J* = 12.1 Hz, 1H); Selected NOEs are between δ 3.45 (H-3) and δ 2.20 (H-4a), between δ 2.34 (H-4b) and δ 4.43 (H-6b), 1.67 (CH₃), and between δ 4.43 (H-6b) and δ 1.67 (CH₃); ¹³C NMR (100.6 MHz, CDCl₃) δ (ppm) 14.0 (q), 14.1 (q), 28.3 (q), 37.6 (d), 38.5 (t), 52.3 (d), 62.08 (t), 62.13 (t), 63.9 (s), 77.5 (t), 167.8 (s), 168.2 (s), 169.6 (s); Selected HMBC correlations are between δ 3.45 (H-3) and δ 169.6 (C-2), 38.5 (C-4), between δ 2.20, 2.34 (H-4a,4b) and δ 169.6 (C-2), 37.6 (C-3), and between δ 4.33, 4.43 (H-6a,6b) and δ 169.6 (C-2), 63.9 (C-5); IR (neat) 2983, 1738, 1464, 1448, 1373, 1332, 1274, 1213, 1179, 1032 cm⁻¹; MS (EI) *m/z* 308 (M⁺, 0.6%), 306 (M⁺, 1.4), 271 (100%); HRMS M⁺ 306.0871, 308.0851 (calcd for C₁₃H₁₉ClO₆ 306.0870, 308.0841).

20: Compound **20** is unstable to column chromatography (SiO₂) and contains a small amount of starting material **18** (eq 11, 0.5 mmol scale, 64 mg, isolated yield 42%); colorless oil; ¹H NMR (400 MHz, CDCl₃) δ (ppm) 1.26 (t, *J* = 7.1 Hz, 3H), 1.31 (t, *J* = 7.1 Hz, 3H), 1.78 (narrow multiplet, 3H), 4.10 (d, *J* = 10.4 Hz, 1H), 4.17–4.31 (m, 4H), 4.61 (d, *J* = 13.0 Hz, 1H), 4.64 (d, *J* = 13.0 Hz, 1H), 4.84 (d, *J* = 10.4 Hz, 1H), 4.98 (m, 1H), 5.05 (m, 1H); ¹³C NMR (100.6 MHz, CDCl₃) δ (ppm) 14.0 (q), 14.1 (q), 19.4 (q), 52.7 (d), 56.3 (d), 62.4 (t), 62.5 (t), 69.6 (t), 114.1 (t), 139.0 (s), 165.6 (s), 166.0 (s), 167.5 (s); IR (neat) 2984, 1748, 1659, 1447, 1370, 1306, 1258, 1164, 1028 cm⁻¹; MS (EI) *m/z* 309 ([M + 1]⁺, 25), 307 ([M + 1]⁺, 100%); HRMS M⁺ 306.0872, 308.0846 (calcd for C₁₃H₁₉ClO₆ M⁺ 306.0870, 308.0841).

■ ASSOCIATED CONTENT

Supporting Information

The additional proposed reaction mechanism for the model compounds, Cartesian coordinates of the optimized geometries, ¹H and ¹³C NMR spectral data, and 2D NOESY spectra. This information is available free of charge via the Internet at <http://pubs.acs.org>.

■ AUTHOR INFORMATION

Corresponding Author

*E-mail: yamazaks@nara-edu.ac.jp.

Notes

The authors declare no competing financial interest.

■ ACKNOWLEDGMENTS

This work was supported by the Ministry of Education, Culture, Sports, Science, and Technology (MEXT), Japan. This work was partly supported by Nanotechnology Platform Program of MEXT, Japan. We thank Mr. M. Takebayashi (Kinki University Technical College) for experimental help. We also thank Prof. S. Umetani (Kyoto University) for elemental analyses.

■ REFERENCES

- (1) For reviews of tetrahydrofurans, see: (a) Keay, B. A.; Hopkins, J. M.; Dibble, P. W. In *Comprehensive Heterocyclic Chemistry III*; Katritzky, A. R., Ramsden, C. A., Scriven, E. F. V., Taylor, R. J. K., Eds.; Elsevier: Amsterdam, 2008; Vol. 3, p 571. (b) Lorente, A.; Lamariano-Merketegi, J.; Albericio, F.; Álvarez, M. *Chem. Rev.* **2013**, *113*, 4567.
- (2) For reviews of pyrrolidines, see: (a) Massiot, G.; Delaude, C. In *The Alkaloids: Chemistry and Pharmacology*; Brossi, A., Ed.; Academic Press: San Diego, CA, 1986; Vol. 27, p 269. (b) Galliford, C. V.; Scheidt, K. A. *Angew. Chem., Int. Ed.* **2007**, *46*, 8748. (c) O'Hagan, D. *Nat. Prod. Rep.* **2000**, *17*, 435. (d) Felpin, F.-X.; Lebreton, J. *Eur. J. Org. Chem.* **2003**, *19*, 3693. (e) Bellina, F.; Rossi, R. *Tetrahedron* **2006**, *62*, 7213.
- (3) For recent examples of tetrahydrofuran syntheses, see: (a) Hanessian, S.; Hou, Y.; Bayraktarian, M.; Tintelnot-Blomley, M. *J. Org. Chem.* **2005**, *70*, 6735. (b) Chavre, S. N.; Choo, H.; Cha, J. H.; Pae, A. N.; Choi, K. I.; Cho, Y. S. *Org. Lett.* **2006**, *8*, 3617. (c) Cheng, X.; Jiang, X.; Yu, Y.; Ma, S. *J. Org. Chem.* **2008**, *73*, 8960. (d) Yu, C.-M.; Youn, J.; Lee, M.-K. *Org. Lett.* **2005**, *7*, 3733. (e) Trost, B. M.; Rey, J. *Org. Lett.* **2012**, *14*, 5632. (f) Evans, P. A.; Inglesby, P. A. *J. Am. Chem. Soc.* **2012**, *134*, 3635.
- (4) For recent examples of pyrrolidine syntheses, see: (a) Trost, B. M.; Silverman, S. M. *J. Am. Chem. Soc.* **2012**, *134*, 4941. (b) Jui, N. T.; Garber, J. A. O.; Finelli, F. G.; MacMillan, D. W. C. *J. Am. Chem. Soc.* **2012**, *134*, 11400. (c) González, A. Z.; Benitez, D.; Tkatchouk, E.; Goddard, W. A., III; Toste, F. D. *J. Am. Chem. Soc.* **2011**, *133*, 5500. (d) Carballo, R. M.; Purino, M.; Ramirez, M. A.; Martín, V. S.; Padrón, J. I. *Org. Lett.* **2010**, *12*, 5334. (e) Schomaker, J. M.; Bhattacharjee, S.; Yan, J.; Borhan, B. *J. Am. Chem. Soc.* **2007**, *129*, 1996. (f) Agbodjan, A. A.; Cooley, B. E.; Copley, R. C. B.; Corfield, J. A.; Flanagan, R. C.; Glover, B. N.; Guidetti, R.; Haigh, D.; Howes, P. D.; Jackson, M. M.; Matsuoka, R. T.; Medhurst, K. J.; Millar, A.; Sharp, M. J.; Slater, M. J.; Toczko, J. F.; Xie, S. *J. Org. Chem.* **2008**, *73*, 3094. (g) Yu, J.-D.; Ding, W.; Lian, G.-Y.; Song, K.-S.; Zhang, D.-W.; Gao, X.; Yang, D. *J. Org. Chem.* **2010**, *75*, 3232.
- (5) Snider, B. B.; Roush, D. M. *J. Org. Chem.* **1979**, *44*, 4229.
- (6) Yamazaki, S.; Yamada, K.; Yamabe, S.; Yamamoto, K. *J. Org. Chem.* **2002**, *67*, 2889.
- (7) (a) Karras, M.; Snider, B. B. *J. Am. Chem. Soc.* **1980**, *102*, 7951. (b) Tietze, L. F.; Beifuss, U.; Ruther, M.; Rühlmann, A.; Antel, J.; Sheldrick, G. M. *Angew. Chem., Int. Ed. Engl.* **1988**, *27*, 1186. (c) Tietze, L. F.; Beifuss, U. *Synthesis* **1988**, 359. (d) Tietze, L. F.; Steinmetz, A. *Angew. Chem., Int. Ed. Engl.* **1996**, *35*, 651.
- (8) (a) Tietze, L. F.; Ruther, M. *Chem. Ber.* **1990**, *123*, 1387. (b) Tietze, L. F.; Schünke, C. *Eur. J. Org. Chem.* **1998**, 2089.
- (9) (a) Snider, B. B. In *Comprehensive Organic Synthesis*; Trost, B. M., Fleming, I., Heathcock, C. H., Eds.; Pergamon Press: Oxford, U.K., 1991; Vol. 2, p 527. (b) Olier, C.; Kaafarani, M.; Gastaldi, S.; Bertrand, M. P. *Tetrahedron* **2010**, *66*, 413. (c) Miles, R. B.; Davis, C. E.; Coates, R. M. *J. Org. Chem.* **2006**, *71*, 1493. (d) Miranda, P. O.; Carballo, R. M.; Martín, V. S.; Padrón, J. I. *Org. Lett.* **2009**, *11*, 357. (e) Chavre, S. N.; Choo, H.; Lee, J. K.; Pae, A. N.; Kim, Y.; Cho, Y. S. *J. Org. Chem.* **2008**, *73*, 7467. (f) Jacolot, M.; Jean, M.; Levoine, N.; van de Weghe, P. *Org. Lett.* **2012**, *14*, 58. (g) Overman, L. E.; Velthuisen, E. J. *J. Org. Chem.* **2006**, *71*, 1581.

(10) (a) Yamazaki, S.; Takebayashi, M. *J. Org. Chem.* **2011**, *76*, 6432. (b) Yamazaki, S.; Takebayashi, M.; Miyazaki, K. *J. Org. Chem.* **2010**, *75*, 1188. (c) Morikawa, S.; Yamazaki, S.; Tsukada, M.; Izuhara, S.; Morimoto, T.; Kakiuchi, K. *J. Org. Chem.* **2007**, *72*, 6459. (d) Yamazaki, S.; Iwata, Y. *J. Org. Chem.* **2006**, *71*, 739.

(11) Formation of **3** presumably arises from participation of adventitious water in situ.

(12) Use of 1 or 2 equiv of SnCl₄ or ZnBr₂ gave the starting material, and BCl₃ gave a complex mixture at room temperature.

(13) Snider and Roush assigned the stereochemistry using coupling constants $J_{3,4}$ by comparison with the reported data (9–12 Hz for 3,4-*trans*; 5.0–9.0 Hz for 3,4-*cis*). Savastianoff, D.; Pfau, M. *Bull. Soc. Chem. Fr.* **1967**, 4162. 3,4-*trans* coupling constants $J_{3,4}$ determined by NOESY for 2-oxotetrahydrofurans in this work range from 5.7 to 10.8 Hz (**2a** (8.4 Hz), **2b** (8.6 Hz), **7a** (8.0 Hz), **7b** (8.1 Hz, 8 Hz in ref 5), **13** (10.1 Hz), **15** (5.7 Hz), and **16** (10.8 Hz)).

(14) Chemical shifts of H-3 and H-4 for Cl- and Br-adducts **9a,b,d,e,g,h** are overlapped in CDCl₃. They are separated in C₆D₆.

(15) The 3,4-*trans* coupling constants $J_{3,4}$ (7.3–7.9 Hz) determined by NOESY for 2-oxopyrrolidines in this work (**9a** (7.5 Hz), **9b** (7.3 Hz), **9c** (7.2 Hz), **9d** (7.7 Hz), **9f** (7.5 Hz), **9g** (7.3 Hz), **9h** (7.5 Hz), **9i** (7.3 Hz), and **11** (7.9 Hz)) are in agreement with the reported data (J_{trans} = 6–8 Hz) for some 2-oxopyrrolidines. (a) Yang, D.; Lian, G.-Y.; Yang, H.-F.; Yu, J.-D.; Zhang, D.-W.; Gao, X. *J. Org. Chem.* **2009**, *74*, 8610. (b) Yang, D.; Yan, Y.-L.; Law, K.-L.; Zhu, N.-Y. *Tetrahedron* **2003**, *59*, 10465.

(16) Calculations of 1:1 complex of the substrate and AlCl₃ were also examined. Although the concerted formations of both 3,4-*cis* and *trans*-tetrahydrofuran rings by intramolecular Cl⁻ attack were calculated, they have higher activation energies (ΔG^\ddagger) than the systems of the substrate and Al₂Cl₆.


(17) Lewis acid-promoted ene reactions leading to *trans*-3,4 stereochemistry preferably have been reported (refs 7b–d).

(18) Yamazaki, S.; Ohmitsu, K.; Ohi, K.; Otsubo, T.; Moriyama, K. *Org. Lett.* **2005**, *7*, 759.

(19) (a) Reetz, M. T. *Angew. Chem., Int. Ed. Engl.* **1972**, *11*, 129. (b) Reetz, M. T. *Angew. Chem., Int. Ed. Engl.* **1972**, *11*, 131. (c) Reetz, M. T. *Tetrahedron* **1972**, *29*, 2189. (d) Reetz, M. T. *Adv. Organomet. Chem.* **1977**, *16*, 33. (e) Fernández, I.; Cossío, F. P.; Sierra, M. A. *Chem. Rev.* **2009**, *109*, 6687. (f) Davis, R. L.; Leverett, C. A.; Romo, D.; Tantillo, D. J. *J. Org. Chem.* **2011**, *76*, 7167.

(20) Concerted dyotropic TS of **B3'** to **D3'** could also be calculated. However, the path has high activation energy (ΔG^\ddagger = 61.39 kcal/mol) (Supporting Information).

(21) A referee suggested another reaction mechanism shown below. The mechanism involves formation of a cyclopropane intermediate **G3** from **B3**, via cyclization of the enolate **F3**, along with AlCl₃ and H⁺ transfers. The mechanism will also be examined in the further study. For the related cyclopropane opening, see: (a) Stork, G.; Gregson, M. *J. Am. Chem. Soc.* **1969**, *91*, 2373. (b) Stork, G.; Marx, M. *J. Am. Chem. Soc.* **1969**, *91*, 2371.



(22) (a) Hanson, J. R. In *Comprehensive Organic Synthesis*; Trost, B. M., Fleming, I., Eds.; Pergamon Press: Oxford, U.K., 1991; Vol. 3, pp 705. (b) Trost, B. M.; Xie, J. *J. Am. Chem. Soc.* **2008**, *130*, 6231. (c) Huang, J.; Lebœuf, D.; Frontier, A. J. *J. Am. Chem. Soc.* **2011**, *133*, 6307.

(23) Snider, B. B.; Roush, D. M.; Killinger, T. A. *J. Am. Chem. Soc.* **1979**, *101*, 6023.

(24) (a) Labrecque, D.; Nwe, K. T.; Chan, T. H. *Organometallics* **1994**, *13*, 332. (b) Wu, H.-P.; Aumann, R.; Fröhlich, R.; Wegelius, E. *Organometallics* **2001**, *20*, 2183.